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ABSTRACT 
 
Normal electric activity of the heart consists of repeated cardiomyocyte depolarizations 
and repolarizations. Repolarization of the ventricular action potential is dependent on 
both inward and outward ion fluxes across cell membranes. Repolarization 
abnormalities may predispose to ventricular arrhythmias, and several factors may 
modify repolarization-related arrhythmia vulnerability. Ventricular repolarization 
generates the T wave, that is measured in body surface electrocardiogram, and several 
electrocardiographic measures have been developed both for clinical and research 
purposes to detect repolarization abnormalities. 
 In the series of studies reported here, the aim was to investigate modifiers of 
ventricular repolarization with the focus on the relationship of the left ventricular mass, 
antihypertensive drugs, and common gene variants, to electrocardiographic 
repolarization parameters. The prognostic value of repolarization parameters was also 
assessed. The study subjects originated from a population of more than 200 middle-aged 
hypertensive men attending the GENRES hypertension study, and from an 
epidemiological survey, the Health 2000 Study, including more than 6000 participants. 
Ventricular repolarization was analysed from digital standard 12-lead resting 
electrocardiograms with two QT-interval based repolarization parameters (QT interval, 
T-wave peak to T-wave end interval) and with a set of four T-wave morphology 
parameters. 
 The results showed that in hypertensive men, a linear change in repolarization 
parameters is present even in the normal range of left ventricular mass, and that even 
mild left ventricular hypertrophy is associated with potentially adverse 
electrocardiographic repolarization changes. In addition, treatments with losartan, 
bisoprolol, amlodipine, and hydrochlorothiazide have divergent short-term effects on 
repolarization parameters in hypertensive men. Analyses of the general population 
sample showed that single nucleotide polymorphisms in KCNH2, KCNE1, and NOS1AP 
genes are associated with changes in QT-interval based repolarization parameters but 
not consistently with T-wave morphology parameters. T-wave morphology parameters, 
but not QT interval or T-wave peak to T-wave end interval, provided independent 
prognostic information on mortality. The prognostic value was specifically related to 
cardiovascular mortality. 
 The results indicate that, in hypertension, altered ventricular repolarization is already 
present in mild left ventricular mass increase, and that commonly used antihypertensive 
drugs may relatively rapidly and treatment-specifically modify electrocardiographic 
repolarization parameters. Common variants in cardiac ion channel genes and NOS1AP 
gene may also modify repolarization-related arrhythmia vulnerability. In the general 
population, T-wave morphology parameters may be useful in the risk assessment of 
cardiovascular mortality. The results of this work may help to better understand the 
modifying factors of ventricular repolarization and the prognostic value of 
electrocardiographic repolarization measures. 
 
Keywords: antihypertensive drugs, electrocardiography, epidemiology, genetics, 
hypertension, hypertrophy, left ventricular, mortality, prognosis, QT interval, 
repolarization, T wave. 
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1 INTRODUCTION 
 
Myocardial ventricular repolarization is determined by a balance between inward and 
outward ion currents across cardiomyocyte cell membranes, and disturbances in this 
process may precipitate ventricular arrhythmias. Arrhythmias caused by repolarization 
abnormalties may potentially be malignant and lead to sudden cardiac death, which is a 
global health problem (Huikuri et al. 2001, Zheng et al. 2001). 
Congenital long QT syndrome (LQTS) is a well-characterized monogenic 
repolarization abnormality affecting ion channels, where the patient-attributable risk of 
arrhythmias may be relatively high. Due to its rareness, however, LQTS cannot account 
for the total burden of ventricular arrhythmias seen in the general population. In 
contrast, common variants of repolarization-associated genes, although typically not 
associated with high patient-attributable arrhythmia risk, may nonetheless be significant 
risk modifiers at the population level (Newton-Cheh et al. 2009, Pfeufer et al. 2009). 
The impact of genetic variants differs between populations with different genetic 
backgrounds, and the relationship of common genetic variants to repolarization 
measures has not been previously characterized in a large Finnish population-based 
cohort. 
 Hypertension, or elevated arterial blood pressure, which was prevalent in 26% of 
adults worldwide in 2000 (Kearney et al. 2005), is also a potential risk factor for 
repolarization abnormalities. Hypertension predisposes to left ventricular hypertrophy 
(LVH), which is associated with increased cardiovascular morbidity and mortality, 
including sudden cardiac death (Levy et al. 1990, Haider et al. 1998). Experimental 
evidence suggests that the unfavourable effect of LVH on sudden cardiac death may be 
mediated by arrhythmogenic repolarization abnormalities (Kowey et al. 1991, Yan et al. 
2001), and clinical studies have shown that marked LVH is associated with adverse 
electrocardiographic (ECG) repolarization changes (Oikarinen et al. 2001a, 2002, 
2004b). However, it has been unknown whether even mild hypertension-induced 
structural left ventricular (LV) remodelling, expected to be more common than marked 
LVH, is already associated with adverse ECG repolarization changes. 
 Drug treatments for hypertension are associated with LVH regression, beneficial 
ECG repolarization changes, and improved prognosis (Rials et al. 1998, Rials et al. 
2001, Oikarinen et al. 2003, Okin et al. 2004a). The favourable repolarization changes 
seen after long-term treatments with antihypertensive drugs may be a consequence of 
reverse structural remodelling. However, antihypertensive agents from different drug 
classes may have differing effects on angiotensin II and aldosterone (Burnier and 
Brunner 1992, Siscovick et al. 1994, Hoes et al. 1995, Delpón et al. 2005, Fischer et al. 
2007), which are important blood pressure regulators with direct proarrhythmic 
potential (Delpón et al. 2005, Domenighetti et al. 2007, Fischer et al. 2007). In addition, 
angiotensin II receptor blockers and ß-blockers may have direct antiarrhythmic 
properties (Delpón et al. 2005, Zicha et al. 2006). Therefore, commonly used 
antihypertensive drugs may also have potentially clinically significant short-term 
repolarization effects, although this has not been assessed in previous studies. 
 The ECG T wave is generated by myocardial voltage gradients during ventricular 
repolarization (Yan and Antzelevitch 1998, Yan et al. 2003). The time from QRS onset 
to T-wave end, the QT interval, is used to assess ventricular repolarization, but this 
measure may detect changes only in repolarization duration. In contrast, novel T-wave 
morphology parameters, such as principal component analysis (PCA) ratio, T-wave 
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morphology dispersion (TMD), total cosine R-to-T (TCRT), and T-wave residuum 
(TWR) measure both temporal and spatial repolarization changes (Acar et al. 1999, 
Malik et al. 2000, Okin et al. 2005). Additionally, the T-wave peak to T-wave end 
(TPE) interval measures terminal repolarization, and has been linked experimentally to 
arrhythmogenic repolarization dispersion (Zabel et al. 1995, Yan and Antzelevitch 
1998, Opthof et al. 2007). However, only a few previous studies have examined the 
predictive value of these novel repolarization measures in the general population. 
In the present series of studies, ventricular repolarization was assessed from digital 
standard 12-lead resting ECGs with a comprehensive set of repolarization parameters 
including QT interval, TPE interval, and four T-wave morphology parameters. The 
study population was derived from a hypertension study, well suited to the assessment 
of the association of LV mass (LVM) and antihypertensive drugs, to ECG 
repolarization. Furthermore, a large Finnish population-based survey provided an 
optimal range of study subjects for assessing the relationship between selected common 
gene variants and ECG repolarization parameters, as well as for analysing the predictive 
values of these ECG repolarization measures. 
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2 REVIEW OF THE LITERATURE 
 
2.1 Ventricular repolarization in the myocardium 
 
Membrane currents and the cardiac action potential. Mechanical contraction of the 
myocyte is dependent on electric activity of the cell membrane. In the resting state, cell 
interior voltage is more negative than exterior, corresponding to a negative membrane 
potential of about –90 mV. This potential is generated by different ion concentrations 
between the two sides of the membrane and is ultimately maintained by ion pumps and 
transporters with the aid of energy-dependent mechanisms (Moczydlowski 2003b). 
The action potential is an all-or-nothing event where the cell membrane potential 
rises (depolarization) and falls (repolarization) and is mediated by an integrated activity 
of ion channels embedded in the cell membrane. Ion channels allow ion flow across the 
cell membrane according to their electrochemical gradient, and most of the ion channels 
involved in the action potential are voltage-gated and highly selective to specific ions 
(Moczydlowski 2003a). Depolarizing ion currents make membrane potential more 
positive and trigger action potential if the threshold potential is reached. Repolarizing 
ion currents then make membrane potential gradually more negative, finally restoring it 
to its original resting value. 
Action potential phases and major ion currents of the ventricular cardiomyocyte are 
shown in Figure 1 and Table 1. An external stimulus triggers the action potential, which 
starts with a rapid depolarization (phase 0) caused mainly by inward fast sodium 
current, followed by a downward deflection (phase 1) which is due to transient outward 
potassium current (Levy 2004). The cardiac action potential exhibits an extended 
“plateau” (phase 2), which is generated by an equilibrium between inward L-type 
calcium current (ICa,L) and outward delayed rectifier potassium currents (Levy 2004). 
The rapid repolarization (phase 3) is caused by delayed rectifier potassium currents, 
along with inactivation of ICa,L (Levy 2004). The inward rectifier potassium current is 
active throughout phases 3 and 4, where it acts to restore the membrane resting potential 
in addition to other functions (Moczydlowski 2003a, Cerrone et al. 2006). 
 
Cardiac ion channels. Ion channels are present in the cell membrane of all biological 
cells. There is a wide variety of ion channels, and their function is fundamental for 
several biological processes, such as nerve impulse, hormone secretion, and muscle 
contraction (Moczydlowski 2003b). In cardiomyocytes, ion channels mediate the action 
potential. In addition, they serve as a link between electric excitation and mechanical 
function via calcium-induced calcium release, where calcium influx into the myocyte 
through the ICa,L channels triggers the release of calcium from the sarcoplasmic 
reticulum, the myocyte calcium store (Boulpaep 2003). The increased concentration of 
cytosolic free calcium, in turn, activates muscle contraction, forming a mechanism 
called excitation-contraction coupling (Apkon 2003). 
Ion channels are constructed of proteins arranged around a cell membrane pore, 
typically containing four to six protein subunits or pseudosubunits arranged together 
like a rosette (Moczydlowski 2003b). Each subunit is encoded by a single gene and is 
made up of several transmembrane segments. In addition to the pore-forming subunits 
(α subunits), some ion channels have accessory subunits (named as β, γ, δ etc.), which 
act as channel gating regulators and linkage proteins (Roden et al. 2002). Ion channels 
are classified according to their structural and functional characteristics, such
REVIEW OF THE LITERATURE                    
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Figure 1 Action potential of the ventricular myocyte. Numbers 0 to 4 indicate action potential phases. 
 
 
 
Table 1 Major ion currents* during the ventricular action potential. 
Ion current Ion Action phase/role 
INa Na+ 0 
ICa,L Ca2+ 0–2 
Ito K+ 1 
IKr K+ 3 
IKs K+ 2, 3 
IK(ATP) K+ 3, 4 
IK1 K+ 3, 4 
INa/Ca Na+, Ca2+ ion homeostasis 
INa/K Na+, K+ ion homeostasis 
IpCa Ca2+ ion homeostasis 
*This list is not intended to be exhaustive. ICa,L=L-type calcium current, IK(ATP)=ATP-sensitive potassium 
current, IK1=inward rectifier potassium current, IKr=rapidly activating delayed rectifier potassium current, 
IKs=slowly activating delayed rectifier potassium current, INa=fast sodium current, INa/Ca=sodium-calcium 
exchanger current, INa/K=sodium-potassium pump current, IpCa=plasma membrane ATPase calcium 
current, Ito=transient outward potassium current. 
 
 
as classification by gating, referring to the mechanism that opens and closes the channel. 
The activation of voltage-gated channels is highly dependent on membrane potential. 
As such, in cardiomyocytes, the fast sodium current, ICa,L, transient outward potassium 
current, rapidly activating delayed rectifier potassium current (IKr), and the slowly 
activating delayed rectifier potassium current (IKs) are mediated through voltage-gated 
channels (Moczydlowski 2003a). Cardiac ion channel expression varies between species 
(Nerbonne 2004) and genders (Di Diego et al. 2002). In addition, different regions of 
the heart feature specific ion-current properties (Volders et al. 1999, Antzelevitch and 
Fish 2001, Szentadrassy et al. 2005), as described further in section 2.3. 
1 
2 
0 mV 
3 
0 4 
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2.2 Mechanisms of arrhythmias 
 
Cardiac arrhythmias form a heterogeneous group of abnormalities in the electric activity 
of the heart. The basis for arrhythmias lies either in abnormal electric impulse initiation 
or conduction (Levy 2004). Abnormal electric impulse initiation forms the first category 
of arrhythmias, and involves pace-maker cells that are found in the sinoatrial node 
(normally the primary pace-maker), atrioventricular node, and His-Purkinje system. 
Pace-maker cells may experience diminished or loss of automaticity. In contrast, a 
positive shift in cardiomyocyte resting potential may accelerate activity in pace-maker 
cells (Lederer 2003). Spontaneous depolarizations may also occur in cells that normally 
do not have pace-maker activity, for example in ventricular myocytes. This may occur 
through early or late afterdepolarizations. Early afterdepolarizations appear in the late 
phase of the action potential, before full repolarization, and are caused by the activity of 
ICa,L channels or sodium-calcium exchangers (Roden 2008). There is a direct positive 
correlation between action potential duration and susceptibility to early 
afterdepolarizations, which occur more often with lower rather than higher heart rates 
and in midmyocardial rather than endocardial or epicardial myocytes (Levy 2004). 
Early afterdepolarizations may also be caused by stretch-induced mechanisms (Eckardt 
et al. 2001). Early afterdepolarizations are the arrhythmia trigger mechanism for 
example for torsade de pointes (TdP) tachycardia in most subtypes of LQTS 
(Antzelevitch and Shimizu 2002, Hedley et al. 2009). In contrast, delayed 
afterdepolarizations appear near the very end of the action potential or after full 
repolarization, and occur more often with higher rather than lower heart rates. Delayed 
afterdepolarizations are associated with an increased intracellular concentration of 
calcium, which in turn may activate depolarizing ion channels, triggering an action 
potential (Levy 2004). Delayed afterdepolarizations are responsible for triggering 
arrhythmia, for example in catecholaminergic polymorphic ventricular tachycardia 
(Katra and Laurita 2005). 
Abnormalities in electric conduction form the second main category of arrhythmias. 
Conduction tissue may become less excitable or inexcitable due to depolarization (e.g. 
in ischemia), or abnormal anatomy (e.g. accessory pathway) may be evident causing 
abnormal conduction. Reentry is a conduction disturbance whereby electric impulse 
travels recurrently in a circle within the heart instead of travelling through the heart and 
then stopping until the next impulse. Reentry has three requirements: a closed 
conduction loop, a region of unidirectional functional block within the loop, and a 
sufficiently slow conduction of action potentials around the loop (Lederer 2003). 
Reentry may be responsible for many arrhythmia types, such as atrial and ventricular 
tachycardia and fibrillation (Lederer 2003), and also includes the maintenance of TdP 
(El-Sherif et al. 1997). 
Action potential prolongation and increased dispersion of repolarization are central 
to repolarization-related arrhythmias. In LQTS, action potential prolongation and the 
increased (transmural) dispersion of repolarization and refractoriness, which lead to 
early afterdepolarizations and reentry, form the arrhythmia mechanism (Hedley et al. 
2009). However, repolarization may also be abnormal without action potential 
prolongation, such as is seen in short QT syndrome and Brugada syndrome, where the 
increased dispersion of repolarization and refractoriness underlie the arrhythmia 
vulnerability (Antzelevitch and Oliva 2006). 
Ion channel dysfunction is fundamental for the genesis of several arrhythmias, many 
of which may be seen as an imbalance between depolarizing and repolarizing ion 
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currents. An ion channel may feature gain-of-function or loss-of-function due to a gene 
mutation. Accordingly, congenital mutations in genes affecting the structure and 
function of ion channels and transporters form a heterogeneous group of inherited 
arrhythmia syndromes including, among others, LQTS, short QT syndrome, Brugada 
syndrome, catecholaminergic polymorphic ventricular tachycardia, and the congenital 
forms of atrial fibrillation, sick sinus syndrome, and conduction defects (Lehnart et al. 
2007, Ackerman and Mohler 2010). Ion channel function may also be abnormal due to 
acquired causes, such as drugs, electrolyte imbalances, or bradycardia (Antzelevitch and 
Shimizu 2002). Furthermore, a chronic structural heart disease or abnormality, such as 
hypertophy, may lead to changes both in ion channel gene expresssion and function as 
well as alterations in conduction, intercellular coupling, extracellular matrix, and 
dispersion of refractoriness. These changes are termed “electric remodelling” and 
together contribute to the arrhythmia mechanism and increased arrhythmia vulnerability 
(Hill 2003). 
Altogether, arrhythmia vulnerability is a dynamic process and is dependent on the 
sum of several congenital and acquired factors. Recognition of multiple factors affecting 
the duration of ventricular repolarization and thus the propensity for arrhythmias led to 
the concept of repolarization reserve (Roden 1998). This is a multiple-hit theory, in 
keeping with the idea that the normal heart has some tolerance or reserve against 
excessive prolongation of the QT interval, and an arrhythmia is triggered only if several 
risk factors are present in an individual simultaneously (Roden 1998). 
 
2.3 Ventricular repolarization in the electrocardiogram: T-wave genesis 
 
ECG, a recording of extracellular voltage gradients generated by the heart, is the most 
important tool for diagnosing disturbances in the electric activity of the heart, including 
arrhythmias and repolarization abnormalities. Ventricular depolarization produces the 
ECG QRS complex, and the T wave represents ventricular repolarization (Lederer 
2003). In addition to the T wave, the ST segment and the J and U waves, not discussed 
further here, may be classified as components of ventricular repolarization (Yan et al. 
2003). 
From the vectorcardiographic point of view, ventricular repolarization may be seen 
as a three-dimensional loop, and the T waves in different ECG leads represent the 
projection of the repolarization loop to a specific lead (Kors et al. 2008). However, the 
cellular and ionic mechanisms responsible for the T wave were poorly understood 
throughout almost the entire 20th century. Nearly 20 years ago, a population of 
myocardial cells, M cells, with specific repolarization properties was discovered from 
the midmyocardium (Sicouri and Antzelevitch 1991). M cells have specific ion-current 
features. Compared to epicardial and endocardial myocytes, M cells feature smaller IKs 
as well as larger sodium-calcium exchanger current and larger late sodium current 
(Antzelevitch and Fish 2001). Epicardial and M cells feature prominent transient 
outward potassium current (Antzelevitch and Fish 2001), which also may be more 
dominant in right than left ventricle (Volders et al. 1999). In contrast, densities of IKr 
and inward rectifier potassium current are even in the three myocardial layers 
(Antzelevitch and Fish 2001). M cells have a tendency to prolong their action potential 
more than epicardial or endocardial cells in response to QT-interval prolonging drugs or 
heart-rate slowing (Sicouri and Antzelevitch 1991, Antzelevitch et al. 1999). Different 
                                                                                                                  REVIEW OF THE LITERATURE 
repolarization features of the three myocardial cell layers also seem to be linked to the 
arrhythmogenic mechanism in LQTS, short QT syndrome, and Brugada syndrome 
(Antzelevitch 2008, Hedley et al. 2009). 
After the discovery of M cells, the T wave has been proposed to result mainly from 
voltage gradients on either side of the M cell region (Yan and Antzelevitch 1998, 
Antzelevitch 2007). These transmural gradients are produced by differences in the final 
repolarization of epicardial, endocardial, and midmyocardial myocytes (Yan and 
Antzelevitch 1998). Figure 2 shows the QRS complex and the positive T wave as well 
as contemporaneous action potentials from three different myocardial layers from a 
canine ventricular wedge preparation. The T wave starts to rise when the action 
potentials of different myocardial layers diverge in phase 2, reaches the peak coincident 
with the full repolarization of epicardium, and returns to the baseline when the M region 
has repolarized (Yan and Antzelevitch 1998). In smaller species, the entire endocardium 
has the properties of M cells and the T-wave end coincides with the end of endocardial 
repolarization (Gupta et al. 2008). However, the results from experimental studies using 
animals and cell/wedge preparation samples cannot be directy extrapolated to the whole 
heart in humans, and the role of transmural voltage gradients in the T-wave genesis has 
been questioned by some researchers (Conrath and Opthof 2006). Thus, despite the 
research advances during the past two decades, the debate on human T-wave genesis is 
ongoing. 
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Figure 2 Simultaneous action potentials from epicardial (Epi), endocardial (Endo), and midmyocardial 
(M) regions of a canine ventricular wedge preparation, and the temporal relationship with surface 
electrocardiogram (ECG). TPE=T-wave peak to T-wave end. 
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2.4 Electrocardiographic repolarization parameters 
 
As the evidence that repolarization abnormalities and arrhythmia vulnerability are 
linked together is convincing, efforts have been made to characterize repolarization 
changes for risk evaluation. Repolarization indexes have been studied, for example in 
resting and excercise ECGs as well as in standard 12-lead ECGs and body surface 
potential maps. Unfortunately, finding an informative marker of repolarization 
abnormalities has proven difficult. For clinical purposes, repolarization assessment from 
12-lead resting ECG has been limited mainly to QT-interval measurement and detection 
of “non-specific” changes in the ST segment and/or T wave, which nonetheless provide 
prognostic information (Rose et al. 1978, Kreger et al. 1987, Schillaci et al. 2004). In 
the 1990s, the range of QT-interval durations, the QT dispersion, was studied 
vigorously, but appeared not to be a reliable measure (Malik and Batchvarov 2000, 
Rautaharju 2002). LV wedge preparation studies indicated that the TPE interval may be 
used as an index of repolarization dispersion (Yan and Antzelevitch 1998). More 
complex approaches, including mathematical data processing and analysis of T-wave 
morphology, have already been studied decades ago (Abildskov et al. 1977, Lux et al. 
1981). In 1995, measures called T-wave amplitude (Dekker et al. 1995) and T-wave 
area (Zabel et al. 1995) were presented. In 1997, PCA was applied to 12-lead ECG 
yielding the PCA ratio (Priori et al. 1997). In addition to these measures, many 
potentially useful repolarization parameters assessing the two- or three-dimensional 
shape of the T-wave from standard 12-lead resting ECG have been introduced (Merri et 
al. 1989, Kors et al. 1998, Acar et al. 1999, di Bernardo and Murray 2000, Kardys et al. 
2003, Kanters et al. 2004, Badilini et al. 2008, Graff et al. 2009). 
 
2.4.1 QT-interval based repolarization parameters 
 
QT interval. The time from the QRS onset to the T-wave end, the QT interval, 
encompasses ventricular depolarization and repolarization and is a measure of global 
repolarization duration (Figure 2). The QT interval depends on heart rate as well as on 
gender, age, plasma electrolyte concentrations, use of medications, congenital and 
acquired diseases (Pfeufer et al. 2005). Currently, approximately one third of the 
variation in the QT interval is considered to be heritable (Newton-Cheh et al. 2009). 
Measuring the QT interval from ECG is relatively fast and straightforward. In addition, 
the cellular basis of the QT interval is easily understandable. Consequently, both in 
clinic and research, the QT interval is widely used to detect short QT syndrome, LQTS, 
and disease- and drug-related repolarization effects. However, the QT interval also has 
several limitations: 1) QT interval is affected by changes in the duration of QRS 
complex, 2) precise determination of the T-wave end with acceptable reproducibility 
may be difficult when the T wave is flat, and especially when there is a fusion of T and 
U waves or when the T wave has a bizarre pattern, 3) there are several methods for 
heart-rate adjustment, and each method has weaknesses (Batchvarov et al. 2002b, 
Dogan et al. 2005), 4) changes in the T-wave shape cannot be detected by measuring 
QT interval, 5) there is significant overlap in the QT intervals of healthy subjects and 
those with abnormal repolarization (Vincent el al. 1992). 
Many studies have examined the relationship between QT-interval prolongation and 
adverse outcomes, such as increased risk of cardiovascular morbidity, mortality, 
ventricular arrhythmias, and sudden cardiac death. In LQTS, the duration of the QT 
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interval is a predictor of TdP events (Priori et al. 2003). In general, prolongation of the 
QT interval to a value of 500 ms or over is considered to confer an obvious TdP risk 
(Priori et al. 2003, Roden 2004, Sager 2008). In the general population, however, 
arrhythmia risk associated with a less pronounced QT-interval prolongation is less clear 
(Sager 2008). According to previous epidemiological studies, it has been somewhat 
controversial regarding whether QT-interval prolongation is a risk factor in the general 
population, with some of the studies reporting an elevated risk (Okin et al. 2000a, 
Robbins et al. 2003, Dekker et al. 2004, Straus et al. 2006); while other studies report 
risk increase only in subgroups, such as in subjects with cardiovascular diseases or with 
the most extreme category of QT-interval prolongation (Algra et al. 1991, Schouten et 
al. 1991, Dekker et al. 1994, Karjalainen et al. 1997, Elming et al. 1998, de Bruyne et 
al. 1999), or no risk increase at all (Goldberg et al. 1991). It is possible that 
methodological issues, such as differences in QT-interval measurement techniques 
and/or heart rate-adjustment, may have affected the results in some of the studies 
(Montanez et al. 2004). 
 
T-wave peak to T-wave end (TPE) interval. The TPE interval is measured as the 
interval between T-wave peak and T-wave end (Figure 2). The TPE interval 
corresponds with the interval between the earliest and latest repolarization in the 
ventricle wall. TPE-interval prolongation is thus expected to represent a higher amount 
of transmural dispersion of repolarization or a wider “vulnerable window” during which 
parts of the ventricle have already repolarized while other parts have not, creating a 
milieu favoring reentry. The theory of transmural dispersion of repolarization has been 
well supported by experimental studies using ventricular wedge preparations 
(Antzelevitch et al. 1999, Emori and Antzelevitch 2001). However, some simulation 
studies (Van Huysduynen et al. 2005, Kors et al. 2008), as well as animal studies using 
intact hearts (Xia et al. 2005, Opthof et al. 2007), have suggested that the TPE interval 
may actually reflect global, not transmural, dispersion of repolarization in vivo. Smetana 
et al. (2003) studied the relationship between the TPE interval and heart rate in 24-hour 
ambulatory ECGs and concluded that the TPE interval correlates markedly with heart 
rate. In contrast, the TPE interval was practically independent of heart rate when 
analysed from resting ECGs (Haarmark et al. 2010) or daytime ambulatory ECGs 
(Andersen et al. 2008). It has also been suggested to use the TPE/QT interval ratio 
instead of the TPE interval to eliminate the possible confounding effect of heart-rate 
changes and inter-individual differences of the QT interval (Gupta et al. 2008). 
Several clinical studies have assessed the value of the TPE interval as a surrogate 
marker of repolarization abnormalities, using either resting or ambulatory ECGs in 
relatively small patient groups, and none have been previously reported in large 
population samples. These studies were performed on patients with resistant 
hypertension (Salles et al. 2008), congenital LQTS (Lubinski et al. 1998, Tanabe et al. 
2001, Viitasalo et al. 2002, Takenaka et al. 2003, Jeyaraj et al. 2008, Kanters et al. 
2008), drug-related LQTS (Yamaguchi et al. 2003, Couderc et al. 2009), short QT 
syndrome (Anttonen et al. 2008), Brugada syndrome (Castro Hevia et al. 2006), 
catecholaminergic polymorphic ventricular tachycardia (Viitasalo et al. 2008), 
arrhythmogenic right ventricular cardiomyopathy (Haapalahti et al. 2008), hypertrophic 
cardiomyopathy (Shimizu et al. 2002), acquired bradycardia (Topilski et al. 2007), high 
risk patients with organic heart disease (Watanabe et al. 2004), patients receiving 
implantable cardioverter-defibrillator and cardiac resynchronization therapy (Lellouche 
et al. 2007), and in myocardial infarction patients (Lubinski et al. 2000, Oikarinen et al. 
2001b, Haarmark et al. 2009). Altogether, findings from most of these clinical studies 
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have been promising and suggest that, in agreement with experimental studies, the TPE 
interval may serve as a marker of clinical arrhythmia vulnerability. However, the 
clinical use of the TPE interval requires further validation, and the methodological 
limitation of accurate determination of measurement points, such as the T-wave end, 
must also be acknowledged. 
 
2.4.2 T-wave morphology parameters 
 
Principal component analysis (PCA) ratio. The mathematical technique called PCA 
finds from multidimensional data the main (“principal”) components which best explain 
the variance of the data (Paerson 1901). The technique uses the eight independent ECG 
leads (I, II, V1–6). In electrocardiology, PCA was originally used in body surface 
potential maps, with the aim of characterizing potentials from multiple leads with a few 
principal patterns (Lux et al. 1981, De Ambroggi et al. 1986). In PCA of the T wave, 
the main orthogonal components of the spatial T wave are quantified (Lux et al. 1981, 
De Ambroggi et al. 1986). Priori et al. (1997) adapted PCA to 12-lead ECG and 
hypothesized that the ratio of the second to the first component (PCA ratio; expressed as 
a percentage) may serve as a measure of T-wave complexity because the first 
component contains most of the repolarization energy in normal repolarization, whereas 
repolarization inhomogeneities increase the second and the following components. 
Morphologically, the PCA ratio may be visualized as the ratio of the short axis to the 
long axis of the spatial T-wave loop (Figure 3). Thus, the PCA ratio is a measure of the 
relative roundness or “fatness” of the three-dimensional T-wave loop, with increasing 
values referring to higher amounts of repolarization complexity and increases in the 
roundness of the T-wave loop (Okin et al. 2004b). The repeatability of the PCA ratio is 
considered reliable in serial ECG recordings (Extramiana et al. 2007). 
According to previous studies, the PCA ratio may be used to distinguish patients 
with repolarization abnormalities. Compared to healthy controls, higher PCA values 
were found in LQTS (Priori et al. 1997), hypertrophic cardiomyopathy (Yi et al. 1998), 
and coronary heart disease (Rautaharju 2002). Importantly, the PCA ratio independently 
predicted cardiovascular mortality in the general population (Okin et al. 2002, Okin et 
al. 2005) and in patients with diabetes mellitus (Okin et al. 2004b). In a large sample of 
postmenopausal women, the PCA ratio independently predicted coronary heart disease 
events and congestive heart failure events, but was not a predictor of mortality 
(Rautaharju et al. 2006a,b). 
 
T-wave morphology dispersion (TMD). TMD estimates the variation in T-wave 
morphology between different ECG leads (Acar et al. 1999). First, the three-
dimensional T-wave loop is determined from the singular value decomposition of the 
eight independent ECG leads (Wall et al. 2003). Second, the two-dimensional T-wave 
loop is determined from the singular value decomposition of the three-dimensional T-
wave loop. Third, reconstruction vectors of the eight independent ECG leads onto the 
two-dimensional T-wave loop are calculated. TMD is measured as the average angle 
(unit in degrees) between all T-wave reconstruction vector pairs excluding lead V1 
(Acar et al. 1999) (Figure 4). Similar T-wave morphology in different ECG leads results 
in a small TMD value, and repolarization abnormalities increase the value. 
                                                                                                                  REVIEW OF THE LITERATURE 
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Figure 3 The principal component analysis ratio represents the ratio of the short axis (σ2) to the long axis 
(σ1) of the spatial T-wave loop. 
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Figure 4 The two-dimensional T-wave loop and reconstruction vectors of the eight independent 
electrocardiogram leads onto the loop. The projection plane of the two-dimensional T-wave loop is 
determined by the two biggest components of the singular value decomposition (C1, C2) performed for 
the three-dimensional T-wave loop. T-wave morphology dispersion is measured as the average angle 
between all T-wave reconstruction vector pairs excluding V1, which usually differs from the other leads. 
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In previous studies, TMD was higher in patients with marked LVH (Acar et al. 1999, 
Oikarinen et al. 2002), and in a patient group with various heart diseases (Ono et al. 
2005), when compared to healthy controls. In US male veterans with cardiovascular 
diseases (Zabel et al. 2002) as well as in a general population sample in US Indians 
(Okin et al. 2005), TMD predicted mortality in univariate analyses. In contrast, in 
studies analysing myocardial infarction patients (Zabel et al. 2000), and systolic heart 
failure patients (Huang et al. 2009), TMD was not a mortality predictor. 
 
Total cosine R-to-T (TCRT). TCRT estimates the spatial deviation between 
depolarization and repolarization phases (Acar et al. 1999). TCRT corresponds 
conceptually to the measure called QRS-T angle (Kardys et al. 2003). In part, TCRT 
resembles methodologically an older repolarization measure called ventricular gradient 
(Batchvarov et al. 2002a). When TCRT is quantified, vectors from three-dimensional 
depolarization and repolarization loops are used after singular value decomposition of 
the eight independent ECG leads (Wall et al. 2003). TCRT is then calculated as the 
cosine of the angle between depolarization vector and repolarization vector (Acar et al. 
1999) (Figure 5). TCRT is unitless and it varies between –1 and 1, corresponding to an 
angle of 180º and 0º, respectively. Thus, a high TCRT value refers to a small angle 
between R- and T-wave loop vectors, as is seen when depolarization and repolarization 
phases are normal. 
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Figure 5 The three-dimensional QRS loop and T-wave loop and the respective depolarization and 
repolarization vectors. Total cosine R-to-T reflects the angle (α) between the depolarization and 
repolarization wavefronts. 
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In previous studies, TCRT has correlated with LVM and differed between healthy 
controls and patients with various heart diseases (Acar et al. 1999, Oikarinen et al. 
2002, Ono et al. 2005, Anttonen et al. 2009). TCRT was a univariate predictor of 
mortality in males with cardiovascular diseases (Zabel et al. 2002) as well as in the 
general population (Okin et al. 2005). The QRS-T angle was an independent predictor 
of cardiac mortality in a Dutch general population study with elderly subjects (Kardys et 
al. 2003). In postmenopausal women, the QRS-T angle was one of the dominating 
predictors among several ECG parameters and showed an independent role as a 
predictor of coronary heart disease events, heart failure events, and both all-cause and 
coronary heart disease mortality (Rautaharju et al. 2006a,b). In systolic heart failure, 
TCRT was able to stratify the risk of cardiovascular mortality (Huang et al. 2009). What 
is particular for TCRT, is that several clinical studies have reported its independent 
prognostic value for mortality in myocardial infarction (Zabel et al. 2000, Batchvarov et 
al. 2004, Malik et al. 2004). Some studies on myocardial infarction patients have linked 
low TCRT values specifically to cardiac (Batchvarov et al. 2004, Perkiömäki et al. 
2006) or arrhythmic deaths (Batchvarov et al. 2004, Malik et al. 2004). 
 
T-wave residuum (TWR). After singular value decomposition of the eight independent 
ECG leads (Wall et al. 2003), the first three components represent the three-dimensional 
or “dipolar” signal content. In contrast, the vector magnitude of the fourth to eighth 
components are expected to reflect “non-dipolar” residual components that are 
contained within the ECG but are not reflected in the three-dimensional ECG, thus 
serving as an estimate of (regional) repolarization heterogeneity (Malik et al. 2000). The 
sum of vector magnitude of the fourth to eighth eigenvalues of the T-wave signal gives 
the absolute TWR (in technical units), and the relation between absolute TWR and the 
sum of vector magnitude of the first to eighth eigenvalues gives the relative TWR 
(Malik et al. 2000, Kesek et al. 2004). Higher TWR values are expected to indicate 
higher degrees of ventricular repolarization heterogeneity. Studies in 24-hour 
ambulatory ECGs have suggested that TWR as well as TCRT are dependent on heart 
rate (Smetana et al. 2004). In resting ECGs, however, both TWR and TCRT seem to be 
only weakly influenced by heart rate (Extramiana et al. 2007). Some concerns have 
been raised about the possibility that the repeatability of TWR and TCRT in serial ECG 
recordings is not optimal (Extramiana et al. 2007). 
Both the absolute and relative TWR have been identified as independent predictors 
of all-cause mortality in males with cardiovascular diseases (Zabel et al. 2002), and 
later, absolute TWR was shown to be an independent predictor of all-cause and 
cardiovascular mortality in the general population (Okin et al. 2005). These studies both 
used a set of T-wave morphology parameters and demonstrated that TWR contained the 
highest predictive value among the parameters tested. In postmenopausal women, 
increased absolute TWR was an independent predictor of all-cause mortality but, unlike 
QRS-T angle, did not predict an increase in coronary heart disease events, heart failure 
events, or coronary heart disease mortality (Rautaharju et al. 2006a,b). In haemodialysis 
patients with end-stage renal disease, relative TWR was an independent predictor of 
cardiovascular and arrhythmia-related mortality (Lin et al. 2007). 
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2.5 Modifiers of repolarization 
 
Multiple factors have an impact on arrhythmia vulnerability. These factors may be 
classified into three categories: proarrhythmic substrate, triggers, and 
modifiers/modulators (Malik 2008). Vulnerable cardiac tissue, such as a heart with 
infarction scars, forms the arrhythmia basis (substrate). Immediate causes or 
mechanisms initiating arrhytmia, such as ischemia or a premature beat, are referred to as 
triggers. A factor that alters the electrophysiological properties of the heart, thus 
changing the relationship between the proarrhythmic substrate and trigger, is a modifier. 
Many of the modifiers are considered not to contain high proarrhythmic potential alone 
but, when appearing simultaneously, they may become significant. Established factors 
modifying repolarization (directly or indirectly) include gender, age, heart rate, 
electrolyte imbalances, structural heart diseases, diabetes mellitus, liver malfunction, 
body temperature, autonomic nervous system, drugs (especially those prolonging the 
QT interval), and variants of ion channel genes. 
 
2.5.1 Left ventricular hypertrophy (LVH) 
 
In physiological LVH, the diameter of the LV wall or chamber (or both) increases as a 
response to physical exercise or pregnancy. Causes of pathological hypertrophy include 
hypertension, valvular heart disease, ischemic heart disease, and (primary) hypertophic 
cardiomyopathy. In ventricular volume overload or increased afterload, LVH is a 
secondary adaptive process which enables the heart to maintain normal wall-tension and 
cardiac output. However, pathological hypertrophy is associated with unfavourable 
long-term consequences, such as diastolic dysfunction, impaired coronary blood flow, 
and heart failure (Levy et al. 1996, Erdogan et al. 2007, Paulus et al. 2007). 
Epidemiological studies have confirmed the association between LVH and adverse 
prognosis (Levy et al. 1990, Haider et al. 1998, Vakili et al. 2001, Bombelli et al. 2009), 
as well as the risk reduction in LVH regression (Verdecchia et al. 2003, Okin 2009). 
LVH also predisposes to sudden cardiac death (Haider et al. 1998, Turakhia et al. 2008), 
which is presumed to be caused at least in part by LVH-induced malignant ventricular 
arrhythmias. Hypertrophied myocardium may predispose to arrhythmias by various 
mechanisms. First, myocyte loss and the associated fibrotic replacement slow electric 
conduction and form a substrate for reentry (Choudhury et al. 2002). Second, interstitial 
fibrosis may lead to intercellular uncoupling, which is associated with increased 
dispersion of repolarization (Conrath et al. 2004). Third, the reduced coronary blood 
flow predisposes to ischemia. Fourth, cardiomyocytes in the hypertrophied heart display 
arrhythmogenic alterations in ion channel expression and function. 
Data on hypertrophic electric remodelling in the human ventricle is limited. In 
various experimental models of cardiac hypertrophy the most consistent 
electrophysiological change has been the cardiomyocyte action potential prolongation 
(Ben-David et al. 1992, Rials et al. 1995, Hill 2003, Furukawa and Kurokawa 2006), 
predisposing to afterdepolarizations. Electric remodelling may be non-uniform, further 
increasing the repolarization heterogeneity between different regions of the heart and 
favouring reentry (Kowey et al. 1991, Rials et al. 1995, Furukawa and Kurokawa 2006). 
The mechanism of action potential prolongation has been linked to alterations in 
intracellular calcium homeostasis as well as to changes in both depolarizing and 
repolarizing ion currents, with the decrease in repolarizing potassium currents being the 
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most coherent finding (Hill 2003, Furukawa and Kurokawa 2006). Putative underlying 
changes in signalling pathways have also been described (Furukawa and Kurokawa 
2006). Electric remodelling in hypertrophy and heart failure have common features but 
also dissimilarities (Hill 2003). Myocardial matrix metalloproteinase activation and 
remodelling in the cardiac transverse-tubule system may be important events during the 
unfavourable disease progression from hypertrophy to heart failure (King et al. 2003, 
Wei et al. 2010). 
Clinically, LVH is most often detected with echocardiography and/or ECG. 
Echocardiographically, LVH may be detected with relatively high accuracy, and is 
evaluated from wall-thicknesses and/or by indexing the approximated LVM to body 
size (Lang et al. 2005). Several ECG LVH criteria exist, and most of them are based on 
voltage measurements and feature high specificity and low sensitivity (Truong et al. 
2010). Magnetic resonance imaging (Alfakih et al. 2004) and computer tomography 
(Truong et al. 2010) are more accurate in LVM evaluation, but impractical for solely 
this purpose. Previous clinical studies have shown that LVH is associated with ECG 
repolarization changes, such as QT-interval prolongation and changes in T-wave 
morphology (Yi et al. 1998, Oikarinen et al. 2001a, 2002, 2004b). However, although 
experimental evidence suggests that electric remodelling is an early process (Ben-David 
et al. 1992, Huang et al. 2000), little has been known about the potential clinically 
modifying effect of mild LVH or mild structural LV remodelling on ECG repolarization 
measures. 
 
2.5.2 Drugs 
 
The mechanism of “quinide syncope”, TdP tachycardia, was uncovered in the 1960s 
(Selzer and Wray 1964). Thereafter, it has become evident that both cardiac and non-
cardiac drugs may directly modify cardiac repolarization, and the effect is typically 
observed as QT-interval prolongation with increased risk of TdP. Most drugs exert this 
effect by inhibiting the function of ion channels encoded by KCNH2, thus reducing IKr 
(Haverkamp et al. 2000). In the process of developing new drugs, routine in vitro and in 
vivo evaluation of potential drug-induced adverse repolarization changes is an important 
safety procedure (Haverkamp et al. 2000), and regulatory guidance notes currently 
dictate that the assessment of changes in ECG QT-interval duration and T-wave shape is 
mandatory (Darpo et al. 2006). Quantitative indexes of T-wave morphology have been 
suggested as potentially valuable tools for drug trials (Badilini et al. 2008, Graff et al. 
2009), but the QT interval currently remains the standard for this purpose (Malik 2009). 
Despite the systematic evaluation process in drug development, the risk of drug-induced 
TdP may remain difficult to predict because the individual risk depends on several risk-
modifying factors and, with the exception of most extreme values, the correlation 
between TdP risk and QT-interval prolongation is not strong (Roden 2008, Sager 2008). 
Different drugs may prolong the QT interval similarly, but may still modify 
afterdepolarization-susceptibility and repolarization dispersion differently (Sager 2008). 
The drug may also have an effect on several types of ion channels with a relatively low 
net TdP risk despite the marked QT-interval prolongation (e.g. amiodarone). In 
addition, minor drug-related changes in repolarization measures may be difficult to 
differentiate from their spontaneous, non-drug related variability. As a result, sometimes 
the adverse effect on repolarization becomes evident only after the new drug has been 
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released and widely used (e.g. cisapride, terfenadine). Comprehensive lists of QT-
interval prolonging drugs are available in the Internet (e.g. www.azcert.org). 
Hypertension has been recognised as the leading risk factor for mortality in the 
world, and nearly 30% of the adult population has been projected to have this condition 
(systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) in 
2025 (Kearney et al. 2005). In economically developed countries, approximately one-
half to two-thirds of hypertensives are on antihypertensive medication (Kearney et al. 
2004). Long-term antihypertensive medication is associated with LVH regression and 
beneficial repolarization changes (Malmqvist et al. 2002, Oikarinen et al. 2003, Okin et 
al. 2004a, Okin 2009). The renin-angiotensin-aldosterone system (RAAS) plays a key 
role in the generation of pathological LVH in hypertension (Mehta and Griendling 
2007, Tomaschitz et al. 2010), and antihypertensive dugs that inhibit RAAS, the 
angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, may be 
more efficient in LVH regression compared to other drugs (Ruilope and Schmieder 
2008). In addition, RAAS-inhibiting drugs may directly blunt the proarrhythmic actions 
of RAAS and modify cardiac repolarization by blood pressure-independent mechanisms 
(Caballero et al. 2000, Rials et al. 2001, Delpón et al. 2005). On the other hand, 
antihypertensive agents from other drug classes, such as ß-blockers and diuretics, may 
also have direct repolarization effects as they also can modulate RAAS and blood 
potassium level (Burnier and Brunner 1992, Blumenfeld et al. 1999). There are no 
clinical studies comparing the short-term repolarization effects of antihypertensive 
drugs. Nonetheless, short-term repolarization modifying effects might be significant at 
the population level because antihypertensive drugs are so widely used and a large 
number of hypertensive subjects may have LVH or structural remodelling, which may 
predispose them to repolarization-related arrythmias. The effect might be important 
particularly at the early phase of the treatment, before significant LV reverse 
remodelling has occurred. 
 
2.5.3 Common gene variants 
 
The majority of human genetic variation is expected to be in the form of substitutions at 
single base pairs, that is, single nucleotide polymorphisms (SNPs) (Kruglyak and 
Nickerson 2001). In this variation, a single deoxyribonucleic acid (DNA) nucleotide 
base (adenine, cytosine, guanine, thymine; called as alleles), differs between individuals 
or between paired chromosomes in an individual. Traditionally, the variation is 
classified as polymorphism if the minor (i.e. less frequent) allele frequency in the 
population is 1% or more (Kruglyak and Nickerson 2001). By 2007, more than 3 
million SNPs had been documented (International HapMap Consortium 2007), and their 
linkage to various cardiac and non-cardiac diseases is under investigation. Nearly 10 
million common SNPs are estimated to lie in the human genome (International HapMap 
Consortium 2007), but most of the SNPs may be innocent and without functional 
significance. SNPs may be located in the coding or non-coding sequences of a gene, or 
in the intergenic regions. Furthermore, a SNP may exhibit its effect on a gene by 
residing in the same (disease-causing) gene, but also from another locus, distinct from 
the disease gene (Scicluna et al. 2008). 
Congenital LQTS is caused by a mutation in genes coding for cardiac ion channels 
or, more rarely, other specified cell proteins involved in cardiac repolarization (Hedley 
et al. 2009). Mutations causing LQTS often have a large effect on the QT interval in the 
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affected individual but, because these mutations are rare, they do not explain much of 
the QT-interval variation at the population level. In contrast, the impact of individual 
SNPs on cardiac repolarization may usually be low in a single individual, but because 
SNPs in repolarization-involved genes are more common, they may still have 
significant impact as repolarization modifiers at the population level. 
Polymorphism in liver enzymes has been well-documented as a risk factor for QT-
interval prolongation in the setting of a poor metabolizer and use of QT-interval 
prolonging drug (Lin and Lu 1998). During the last decade, several SNPs have also 
been found in genes coding for ion channels and their regulatory structures, and in vitro 
studies have demonstrated that SNPs may modify ion channel expression, function, and 
localization (Scicluna et al. 2008). Some of the variants are associated with potentially 
harmful, others potentially protective or unknown repolarization effects, and the effect 
may even vary whether the SNP is inherited in cis or in trans with the disease-causing 
allele (Hedley et al. 2009). Table 2 summarizes previous population studies on the 
relationship between the QT interval and SNPs in various LQTS genes. The clinical 
studies have typically used the QT interval as the repolarization measure and indicate a 
cumulative effect of various QT-interval altering SNPs (Pfeufer et al. 2009). Thus, the 
SNPs in LQTS genes play a role as disease modifiers, which in part explain the wide 
variability in the genotype-phenotype relationship in LQTS (Scicluna et al. 2008, 
Hedley et al. 2009). 
Recently, several studies have also confirmed the association between the QT 
interval and polymorphism in the nitric oxide synthase 1 adaptor protein gene 
(NOS1AP), showing QT-interval prolongation with minor alleles (Arking et al. 2006, 
Aarnoudse et al. 2007, Post et al. 2007, Lehtinen et al. 2008, Tobin et al. 2008, Crotti et 
al. 2009, Newton-Cheh et al. 2009, Pfeufer et al. 2009, Raitakari et al. 2009, Tomás et 
al. 2010). NOS1AP may modify repolarization by altering the activities of ICa,L and IKr 
(Chang et al. 2008). Of note, association between NOS1AP polymorphism and sudden 
cardiac death has been reported (Eijgelsheim et al. 2009, Kao et al. 2009). In genome-
wide association studies, an association has been found between the QT interval and 
SNPs in genes which do not contain any established electrophysiological function 
(Newton-Cheh et al. 2009, Pfeufer et al. 2009). In addition, the currently known SNPs 
seem to explain only less than 10% of the variation in QT-interval duration (Newton-
Cheh et al. 2009, Pfeufer et al. 2009), indicating the need for future research. 
 
2.5.4 Gender 
 
It has been well documented that cardiac repolarization exhibits gender differences. 
Previous clinical studies have demonstrated that women have a longer QT interval than 
men (Merri et al. 1989, Smetana et al. 2002, Wu et al. 2003). Furthermore, women 
prolong their QT interval more and have higher risk of TdP than men when using QT-
interval prolonging drugs (Makkar et al. 1993, Benton et al. 2000). Gender may also 
affect the predictive value of QT-interval duration in the general population 
(Karjalainen et al. 1997, de Bruyne et al. 1999). A few clinical studies have also 
reported gender differences in numerical values of the TPE interval (Nakagawa et al. 
2003), PCA ratio (Okin et al. 2000b, Okin et al. 2002), TMD (Ono et al. 2005), TCRT 
(Smetana et al. 2002), TWR (Smetana et al. 2002), and T-wave amplitude (Wu et al. 
2003). Gender differences in the predictive value of T-wave morphology parameters 
have not been previously reported. 
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Table 2 A selection of population studies on the relationship between QT interval and SNPs. 
 
 
 
Gene 
 
 
 
SNP 
Allele* and 
respective 
amino acid 
change 
Minor 
allele 
effect† on 
QT interval 
 
 
 
Reference 
rs757092 A→G ↑ Pfeufer et al. 2005, Gouas et al. 2007 
rs2074238 C→T ↓ Newton-Cheh et al. 2009 
rs12576239 C→T ↑ Newton-Cheh et al. 2009 
KCNQ1 
rs12296050 C→T ↑ Pfeufer et al. 2009 
↑ Pietilä et al. 2002‡, Koskela et al. 2008‡ 
↓ Bezzina et al. 2003, Gouas et al. 2005, 
Pfeufer et al. 2005, Newton-Cheh et al. 2007 
rs1805123 A→C, K897T 
↔ Raitakari et al. 2009 
rs2968863§ G→A ↓ Pfeufer et al. 2009 
rs2968864§ A→G ↓ Newton-Cheh et al. 2009 
rs3807375 G→A ↑ Newton-Cheh et al. 2007 
rs3815459 G→A ↑ Pfeufer et al. 2005 
KCNH2 
rs4725982§ C→T ↑ Newton-Cheh et al. 2009 
rs1805124 A→G, H558R ↑ Aydin et al. 2005, Gouas et al. 2005 
rs11129795 G→A ↓ Pfeufer et al. 2009 
SCN5A 
rs12053903 T→C ↓ Newton-Cheh et al. 2009 
↑ Friedlander et al. 2005¶ rs1805127 G→A, G38S 
↔ Aydin et al. 2005, Akyol et al. 2007, 
Gouas et al. 2007 
↑ Gouas et al. 2005, Newton-Cheh et al. 2009 
KCNE1 
rs1805128 G→A, D85N 
↔ Aydin et al. 2005, Friedlander et al. 2005 
↑ Aydin et al. 2005 KCNE2 rs2234916 A→G, T8A 
↔ Pfeufer et al. 2005 
KCNJ2 rs17779747§ G→T ↓ Pfeufer et al. 2009 
*Major→minor allele. †Prolonging effect=↑, shortening effect=↓, non-signicant effect=↔. ‡The effect 
was significant in women only and nonsignificant in men. §Located near the respective gene. ¶The effect 
was significant in men only and nonsignificant in women. SNP=single nucleotide polymorphism. 
 
 
 
 
Gender difference in QT-interval duration appears after puberty when boys’ QT 
interval shortens (Rautaharju et al. 1992), which suggests a gonadal-hormone mediated 
mechanism. Indeed, compared to controls, castrated men have prolonged repolarization 
and women with virilization have shortened repolarization (Bidoggia et al. 2000), which 
suggests that testosterone may have an important role in modulating (i.e. shortening) 
repolarization. Studies on women receiving hormone replacement therapy also indicate 
that estrogen may prolong the QT interval, and that progesterone may counteract this 
effect (Carnethon et al. 2003, Kadish et al. 2004, Gökçe et al. 2005). Although results 
vary according to the animal model, experimental studies have shown that the 
expression of several myocardial ion channels may vary between genders, and that 
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gonadal hormones may have effects on myocardial ion channels both via genomic and 
non-genomic pathways (Cheng 2006, Yang et al. 2010). Data on gender differences in 
myocardial ion channels in humans is limited. In failing human LV myocytes, women 
may have larger ICa,L and smaller transient outward potassium current than men 
(Verkerk et al. 2005). Ultimately, gender differences in repolarization may in part be 
explained by gender differences in autonomic nervous system function (Nakagawa et al. 
2009). 
 
2.6 Summary 
 
Function of the heart is dependent on electric activity of the cardiomyocytes whose 
action potentials are produced by a coordinated function of depolarizing and 
repolarizing ion currents through ion channels. Abnormal ventricular repolarization may 
predispose to arrhythmias, and repolarization-related arrhythmia vulnerability may be 
modified by several factors. Previously, little has been known about the ECG 
ventricular repolarization modifying effects of mild LVM increase and antihypertensive 
drugs in hypertension, as well as of SNPs in the Finnish general population. 
In a standard 12-lead resting ECG, the duration of ventricular repolarization, the QT 
interval, has long been the most widely used repolarization parameter both clinically 
and in research. Efforts have been made to develop additional repolarization measures 
for risk stratification. Previous experimental and clinical studies suggest that the TPE 
interval may quantify arrhythmogenic repolarization dispersion. Furthermore, 
parameters evaluating temporospatial changes in the ventricular repolarization have 
been developed using computerized analysis of digital ECG. Previous clinical studies 
suggest that evaluation of T-wave morphology may differentiate between healthy 
individuals and those with repolarization disturbances, and that parameters such as PCA 
ratio, TMD, TCRT, and TWR contain independent prognostic information. Few 
previous studies have assessed the predictive value of T-wave morphology parameters, 
and none have reviewed the predictive value of the TPE interval, in the general 
population. 
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3 AIMS OF THE STUDY 
 
The series of studies reported were undertaken to investigate modifiers of ECG 
repolarization parameters, and to assess the predictive value of these repolarization 
parameters for mortality. Specific aims were: 
 
• To study whether mild LVM increase in hypertension is associated with ECG 
repolarization changes (study I). 
 
• To investigate whether ventricular repolarization can be modified by the type of 
antihypertensive drug treatment (study II). 
 
• To evaluate the relationship of common variants in NOS1AP and selected LQTS 
genes to ECG QT interval (study III), as well as to TPE interval and T-wave 
morphology parameters (study IV). 
 
• To examine the predictive value of ECG QT interval and T-wave morphology 
parameters for all-cause and cardiovascular mortality in the general population 
(study V). 
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4 MATERIALS AND METHODS 
 
4.1 Study subjects 
 
In studies I and II, the study subjects originated from the GENRES study (a 
randomized, double-blind, cross-over, single-centre, placebo-controlled study on the 
molecular genetics of drug responsiveness in essential hypertension) (Hiltunen et al. 
2007). The clinical part of the GENRES study was conducted at the Helsinki University 
Central Hospital in 1999–2004, and the study was approved by the Ethics Committee of 
Helsinki University Central Hospital and the National Agency for Medicines of Finland. 
The study subjects were white men aged 35–60 years with either prior antihypertensive 
drug treatment or diastolic blood pressure ≥95 mmHg on three separate measurements. 
All subjects were in sinus rhythm. Secondary hypertension, treatment with three or 
more antihypertensive drugs, drug-treated diabetes mellitus, congestive heart failure, 
and coronary heart disease were among the exclusion criteria. In study I, those 
GENRES study subjects were included who had both ECG and transthoracic 
echocardiogram recorded during the study run-in placebo period. Subjects with 
complete bundle branch block, ECG strain pattern of repolarization, or non-optimal 
ECG quality were excluded, and study I eventually included 220 subjects. In study II, 
those GENRES study subjects who had both ECG recorded and office blood pressure 
measured at the end of all four drug periods were considered eligible. Subjects with 
complete bundle branch block were excluded, and hence study II included 183 subjects. 
In studies III–V, the study population was derived from an epidemiological survey, 
the Health 2000 Study, which was conducted in Finland in 2000–2001 with the 
permission of the Epidemiology Ethics Committee of the Helsinki and Uusimaa 
Hospital Region (Aromaa and Koskinen 2004). The Health 2000 Study population was 
a two-stage stratified cluster sample of 8028 Finnish adults aged ≥30 years. DNA 
samples were collected from 6334 subjects, and ECGs were available from 6292 
subjects. In studies III–V, exclusion criteria were complete bundle branch block, QRS 
duration ≥120 ms (in study III only), Wolff-Parkinson-White pattern, paced rhythm, 
atrial fibrillation or flutter, poor ECG quality, confirmed genetic diagnosis of Finnish 
LQTS founder mutation (in studies III and IV only), and use of medication with 
possible effect on QT-interval duration. After exclusions, study III included 5043 
subjects, study IV 5890 subjects, and study V 5917 subjects. 
 
4.2 Clinical evaluation 
 
In studies I and II, the subjects underwent a structured health interview, measurements 
(e.g. height, weight, ECG), and a physician’s clinical examination at the screening visit 
of the GENRES study (Hiltunen et al. 2007). The study started with a four-week run-in 
placebo period, before which the subjects discontinued their possible previous 
antihypertensive medications. Transthoracic echocardiogram and ECG recording was 
performed at the end of the run-in placebo period. The subjects then received one of the 
four study drugs in a randomized order daily for four weeks, and placebo periods of 
four weeks were included between drug periods. The study drugs were, administered 
once daily doses of losartan 50 mg, bisoprolol 5 mg, amlodipine 5 mg, and 
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hydrochlorothiazide 25 mg. ECG was recorded, blood samples (serum potassium and 
fasting blood glucose were used in studies I and II) were taken, and office blood 
pressure and ambulatory blood pressure were measured at the same visit at the end of 
each placebo and drug period. Thus, for studies I and II, ECG and blood pressure data 
were gathered during eight different occasions (during treatment with four different 
antihypertensive drugs and during four placebo periods) from every study subject. The 
non-dominant arm was used to measure blood pressure. Office blood pressure 
measurements (Omron M4, Omron Healthcare, Tokyo, Japan) were performed after a 
30-minute rest in sitting position three times with one minute intervals, and the mean of 
the last two measurements was used in the analyses (studies I and II). In study II, the 
average value of office blood pressure measurements from all four placebo periods was 
used as a reference to which measurements during each drug period were compared. 
The 24-hour ambulatory blood pressure, used in study I, was measured according to the 
guidelines of the European Society of Hypertension (O’Brien et al. 2003). 
In studies III–V, clinical data were based on examinations performed at the Health 
2000 Study baseline and included health questionnaires, measurements (e.g. height, 
weight, blood pressure, ECG), and a physician’s clinical examination (Aromaa and 
Koskinen 2004). Disease definitions used in studies IV and V are listed in Appendix 1. 
Blood samples were taken after an overnight fast, and the total cholesterol/high density 
lipoprotein ratio was used in study V. Office blood pressure was measured from the 
right arm with a conventional mercury sphygmomanometer after a 10-minute rest in the 
sitting position twice with a two-minute interval. The mean of two blood pressure 
readings was used in studies III–V. In study V, both the mortality status and cause of 
death of the subjects were obtained from the Causes-of-Death Register maintained by 
Statistics Finland. 
 
4.3 Electrocardiographic measurements 
 
ECG recordings. In studies I–V, a digital standard resting 12-lead ECG was recorded 
with a Marquette MAC 5000 electrocardiograph (GE Marquette Medical Systems, 
Milwaukee, Wisconsin, USA). The 12 leads were recorded simultaneously. The digital 
median QRS-T complex automatically produced by QT Guard 1.3 software (GE 
Marquette Medical Systems) was used for measurements in each lead. In study II, the 
average values of ECG measurements from all four placebo periods were used as a 
reference to which measurements during each drug period were compared. ECGs used 
in studies III–V were classified according to guidelines from the Minnesota Code 
Manual (Prineas et al. 1982). 
 
Adjustment for heart rate. In studies I–V, heart rate was automatically provided by 
QT Guard 1.3 software. In studies I and II, QT intervals were adjusted for heart rate 
with the nomogram method (yielding QTNc interval) (Karjalainen et al. 1994) with the 
correction numbers adopted from a study population closely resembling the population 
in studies I and II (Karjalainen et al. 1994). In studies III–V as well, QT intervals were 
adjusted with the nomogram method, but the rate-correction equations were determined 
in the study population which was used in these studies. The correction equations were 
determined separately for each 10 beats per minute heart rate range based on the 
previous description (Karjalainen et al. 1994). In studies IV and V, the equations were 
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calculated separately for both genders. To also compare our results to previous studies, 
Bazett’s formula adjustment (QTc interval=QT interval/RR interval0.5) was calculated 
(Bazett 1920) in studies III and V. TPE intervals were not rate-adjusted (Andersen et al. 
2008). 
 
QT intervals and TPE intervals. QT-interval measurements were performed based on 
a previously described and validated algorithm (Oikarinen et al. 1998) with a custom-
made software. The software calculated the QTpeak (from QRS onset to T-wave peak), 
QTend (from QRS onset to T-wave end), TPE interval, as well as QRS duration in each 
lead. A single observer reviewed measurements on-screen in a blinded fashion, and 
leads with low signal-to-noise ratio or flat T waves were excluded from QT- and TPE-
interval analyses. In study I, QT and TPE intervals had to be measurable in ≥6 leads 
with ≥3 precordial leads for the ECG to be included in the study. For final analyses, the 
maximum QTpeak (studies I and II) and mean QTpeak (study II) interval of all leads, 
maximum QTend (studies I, II, V) and mean QTend (studies II and III) interval of all 
leads, maximum TPE interval of precordial leads (studies I, II, IV, V), and mean TPE 
interval of all leads (studies I and II) were used. In study IV, SNP effects on QTpeak and 
QTend intervals were analysed from the precordial lead with the maximum TPE interval. 
 
T-wave morphology parameters. All T-wave morphology parameters (studies I, II, 
IV, V) were calculated fully automatically by computer. QT Guard 1.3 software was 
used to measure the PCA ratio. Three additional T-wave morphology parameters (TMD, 
TCRT, TWR) were calculated by custom-made software, which uses a previously 
described algorithm (Acar et al. 1999, Oikarinen et al. 2002). The procedure involves 
singular value decomposition (Wall et al. 2003) of eight independent leads (I, II, V1–6) 
and reconstruction of an eight-lead orthogonal system. In such a system, the first three 
components correspond to the energy in the three-dimensional ECG vector (dipolar 
components), and the five remaining components correspond to the non-dipolar signal 
content of the original ECG (Acar et al. 1999, Malik et al. 2000) (see Appendix 2 for 
computation description). The absolute (not the relative) TWR was used as the measure 
of non-dipolar signal content (studies I, IV–V). T-morphology parameters showed non-
significant or only weak correlations to heart rate (absolute r values from 0.005 to 0.08 
in studies IV and V). 
 
Other ECG measurements. Custom-made software was also used to automatically 
measure R- and S-wave amplitudes (measured separately in each lead) as well as QRS 
duration (the same value used for all leads), and the results were reviewed on-screen in 
a blinded fashion by a single observer. With the 10 mm/mV calibration, Sokolow-Lyon 
voltage (SV1+RV5 or SV1+V6) >35 mm and Cornell voltage-duration product 
[(SV3+RaVL+8 in women)×QRS duration] ≥2440 mm×ms (Molloy et al. 1992) were 
used as ECG indexes of LVH. In studies III–V, ECG LVH was considered to be present 
if either of the criteria were fulfilled. In study I, the Cornell voltage-duration product 
was used as the sole criterion. In study II, the sum of QRS areas in all 12 ECG leads 
(QRS area sum) was calculated (Oikarinen et al. 2004a). The QRS area sum during 
placebo correlated with echocardiographically determined LVM index (LVMI) (r=0.41, 
P<0.001) and served as an estimate for LVM changes. 
 
Reproducibility of ECG repolarization parameters. To test the intraobserver 
variability of ECG measurement techniques, repolarization measurements were 
performed twice from the same recordings in study I. The intraobserver coefficient of 
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variation was 1.5% for the maximum QTpeak interval of all leads, 1.3% for the 
maximum QTend interval of all leads, 2.7% for the maximum TPE interval of precordial 
leads, 1.7% for the mean TPE interval of all leads, 0.0% for the PCA ratio, 1.6% for 
TMD, 0.0% for TCRT, and 2.5% for TWR. 
 
4.4 Echocardiographic measurements 
 
An experienced cardiologist performed echocardiograms during the run-in placebo 
period and stored two-dimensionally guided M-mode recordings on videotapes (studies 
I and II). Interventricular septal thickness, posterior wall thickness, and LV end-
diastolic diameter were later measured on-screen by a single observer according to the 
recommendations of the American Society of Echocardiography (Sahn et al. 1978). 
Measurements were averaged from five cardiac cycles. Ejection fraction was calculated 
with the Teichholz method. LVM (in grams) was calculated by an anatomically 
validated formula 0.8×[1.04×((interventricular septal thickness+LV end-diastolic 
diameter+posterior wall thickness)3–LV end-diastolic diameter3)]+0.6 (Devereux et al. 
1986), and LVMI by dividing LVM by body surface area (in square metres). The 
Mosteller formula [(height in centimetres×weight in kilograms)/3600]0.5 was used to 
calculate body surface area (Mosteller 1987). LVMI >116 g/m2 was used for LVH 
detection (Liu and Devereux 1998). 
 
4.5 Genetic studies 
 
In study III, the SNPs in NOS1AP and LQTS genes were selected based on their 
previous identification in the Finnish population and on the previous evidence of their 
functional role as a repolarization modifier (Fodstad et al. 2004, Arking et al. 2006, 
Aarnoudse et al. 2007). In study IV, seven SNPs were selected based on their shortening 
or prolonging effects on the QT interval in study III. 
Peripheral blood sample lymphocytes were used for DNA analyses (studies III and 
IV). For KCNH2 K897T, genotyping was performed using a Taqman Genotyping Assay 
(Applied Biosystems, Foster City, California, USA), which detects the alleles at the 
SNP site with fluorescence-labeled detectors. The fluorescence signals were measured 
with 7900HT Real Time PCR System (Applied Biosystems), and SDS2.2 software 
(Applied Biosystems) was used in analysing the data. For all other SNPs, genotyping 
was performed using Sequenom MALDI-TOF mass spectrometry (MassArray Compact 
Analyzer, Sequenom Inc., San Diego, California, USA), which utilizes primer extension 
reaction chemistry. In MALDI-TOF assays, the homogenous MassEXTEND method 
was used for KCNH2 R1047L and the iPLEX chemistry for all other SNPs. Reactions 
for the MALDI-TOF assays were designed with Sequenom Assay Designer 3.1 
software (Sequenom Inc.), and SpectroAnalyzer 3.4 software was used to assess the 
results. 
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4.6 Statistical analyses 
 
Analyses were performed with SPSS 13.0 and 15.0 software (SPSS Inc., Chicago, 
Illinois, USA). Values are presented as mean±standard deviation (SD) for continuous 
variables and as number of subjects or percentages for categorical variables. Variable 
distributions were assessed with histograms and the Kolmogorov-Smirnov test, and the 
appropriate test was selected according to the distribution. In categorical variables, 
groups were compared with the Chi-square test. In continuous variables, the Mann-
Whitney U test or independent samples t test (two-group comparison) or analysis of 
variance (multiple-group comparison) was used to compare groups. In repeated 
measures, either the repeated measures analysis of variance or Friedman test was used 
to compare groups. The Spearman test or Pearson’s test was used to assess univariate 
correlations. Regression analyses were used to assess the relationship between 
independent and dependent variables. To normalize variable distributions in regression 
analyses, natural-logarithmic (loge) transformation or the Blom method (Blom 1958) 
was used. In study I, the relationship of repolarization parameters to five ordered LVMI 
categories was analysed with the Jonckheere-Terpstra test. In studies III and IV, the 
prevalence estimates were derived from the weighted study population, and the size 
effects of genetic variants to repolarization parameters were assessed with linear 
regression analyses including both additive and genotypic models. The additive model 
was a one degree of freedom model (the genotype was transformed to a variable which 
corresponded to the number of minor alleles) and the genotypic model was a two 
degrees of freedom model (the heterozygote and minor homozygote genotypes were 
converted to two dichotomous variables). All SNPs were tested for Hardy-Weinberg 
equilibrium with a Chi-square test. In study V, analyses were performed separately for 
men and women. In study V, the Kaplan-Meier curves and log-rank tests were used to 
assess the death rates in the groups dichotomized according to the median values of the 
repolarization parameters, and the Cox proportional hazards models were used to assess 
the relationship of repolarization measures and clinical variables to time to death. A 
two-tailed P<0.05 was considered statistically significant. 
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5 RESULTS 
 
5.1 Relationship of repolarization parameters to left ventricular mass 
   (study I) 
 
For study I, 220 hypertensive men with a mean age of 51±6 years were subjects. No 
wall-motion abnormalities were seen with echocardiography, whilst mean LV ejection 
fraction was 62±7%, mean LVM 203±39 g, and mean LVMI 99±19 g/m2. Only 39 
subjects (18%) reported echocardiographic LVH, and only nine subjects (4%) 
demonstrated ECG LVH. 
Table 3 shows repolarization parameters as well as clinical and echocardiographic 
variables relative to the echocardiographic LVH status. Of the clinical parameters, only 
24-hour mean systolic blood pressure differed significantly between the groups. QT 
intervals, TPE intervals, PCA ratio, TMD, and TWR were higher in LVH versus non-
LVH subjects, whereas TCRT was lower, as expected. To further study the relationship 
of repolarization parameters to LVM, five ordered LVMI categories were created and 
significant linear trends observed across the categories for all repolarization parameters 
(Figure 6). Five ordered LVMI categories in subjects without echocardiographic LVH 
were also created, and significant linear trends were observed for PCA ratio (P<0.001), 
TMD (P<0.001), TCRT (P=0.032), and TWR (P=0.025). 
When ECG repolarization parameters and selected clinical and echocardiographic 
variables (age, body mass index, office and 24-hour mean systolic and diastolic blood 
pressure, blood glucose, serum potassium, interventricular septal thickness, LV end-
diastolic diameter, LVMI) were correlated, the strongest correlation was observed 
between TMD and LVMI (r=0.39, P<0.001), and interventricular septal thickness and 
LVMI were the only variables that correlated statistically significantly with all ECG 
repolarization parameters (absolute r values from 0.15 to 0.29 for interventricular septal 
thickness and from 0.16 to 0.39 for LVMI). Multiple linear regression analyses 
including significant clinical variables and repolarization parameters showed that 
LVMI, though not an independent determinant of the QTpeak interval, was an 
independent determinant of all other repolarization parameters (P from 0.048 to 
<0.001). 
 
5.2 Electrophysiological effects of losartan, bisoprolol, amlodipine, and 
   hydrochlorothiazide (study II) 
 
The mean age of the 183 hypertensive men in study II was 51±6 years. Table 4 shows 
the effects of antihypertensive treatment with losartan, bisoprolol, amlodipine, and 
hydrochlorothiazide on clinical and ECG parameters. Compared to placebo, both 
systolic and diastolic blood pressures were significantly lower during drug 
administration, but hydrochlorothiazide lowered blood pressure the least. 
Hydrochlorothiazide increased and losartan decreased the QRS area sum. Compared to 
serum potassium during the study run-in placebo period, serum potassium increased 
during bisoprolol and decreased during hydrochlorothiazide. Both losartan and 
bisoprolol shortened all studied QT intervals and the mean TPE interval, decreased TMD 
                                                                                                                                                         RESULTS 
Table 3 Characteristics of study subjects by LVH status in study I (LVH + if LVMI >116 g/m2). 
Values are expressed as mean±standard deviation. The t test or *Mann-Whitney U test. LV=left 
ventricular, LVH=left ventricular hypertrophy, LVM=left ventricular mass, LVMI=left ventricular mass 
index, Nc=nomogram-corrected for heart rate, PCA=principal component analysis, QTend=QT interval to 
the T-wave end, QTpeak=QT interval to the T-wave peak, TCRT=total cosine R-to-T, TMD=T-wave 
morphology dispersion, TPE=T-wave peak to T-wave end interval, TWR=T-wave residuum. 
 LVH – (n=181) LVH + (n=39) P 
Age (years)   50±7   52±5 <0.084 
Body mass index (kg/m2)   26.9±2.8   26.8±2.8 <0.795 
Body surface area (m2)     2.1±0.1     2.0±0.1 <0.286 
Office systolic blood pressure (mmHg)   150±16   155±16 <0.106 
Office diastolic blood pressure (mmHg) 100±9 100±9 <0.706 
24-hour mean systolic blood pressure (mmHg)   133±11   137±12 <0.045 
24-hour mean diastolic blood pressure (mmHg)   92±7   94±6 <0.100 
Serum potassium (mmol/L)     4.4±0.2     4.4±0.2 <0.417 
Ejection fraction (%)   62±7   60±8 <0.077 
Interventricular septal thickness (mm)   10.7±1.4   13.1±1.6 <0.001 
Posterior wall thickness (mm)   10.4±1.3   12.3±1.4 <0.001 
LV end-diastolic diameter (mm)   49±4   51±4 <0.001 
LVM (g)   190±29   261±26 <0.001 
LVMI (g/m2)     92±13   128±10 <0.001 
Maximum QTendNc (ms)   400±21   410±23 <0.007 
Maximum QTpeakNc (ms)   330±18   337±20 <0.028 
Maximum TPE V1–6 (ms)     82±12     89±13 <0.001 
Mean TPE (ms)   72±7   76±6 <0.003 
PCA ratio (%)   12.9±4.9   16.3±6.1 <0.002 
TMD* (°)   11.1±6.2     16.6±12.3 <0.001 
TCRT* (unitless)     0.45±0.45     0.22±0.54 <0.006 
TWR* (technical units)     12965±12292     16943±17852 <0.035 
 
 
 
 
and increased TCRT. In addition, losartan shortened the precordial maximum TPE 
interval and decreased the PCA ratio. Hydrochlorothiazide prolonged both studied TPE 
intervals, but did not have an effect on the other repolarization parameters. Amlodipine 
had no significant ECG repolarization effects. Figure 7 shows the changes in ECG 
repolarization parameters, in percentages, during each drug treatment compared to 
placebo. 
To determine the factors associated with changes in ECG repolarization parameters, 
they were correlated to the changes in systolic blood pressure, QRS area sum, and 
serum potassium level after the 4-week treatment. A decrease in systolic blood pressure 
was associated with shortening of QT intervals (r from 0.09 to 0.16, P from 0.011 to 
<0.001) and TPE intervals (r from 0.10 to 0.13, P from 0.005 to <0.001) as well as with 
an increase in TCRT (r=–0.09, P=0.015). A decrease in the QRS area sum was associated 
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Figure 6 Linear trends for repolarization parameters in five ordered LVMI categories with equal ranges 
of LVMI values in study I (LVMI 55–74 g/m2, n=18; 75–94 g/m2, n=85; 95–114 g/m2, n=76; 115–134 
g/m2, n=33; 135–154 g/m2, n=8). Bars represent medians. P values from the Jonckheere-Terpstra test. 
LVMI=left ventricular mass index, Max=maximum, Nc=nomogram-corrected for heart rate, 
PCA=principal component analysis, QTend=QT interval to the T-wave end, QTpeak=QT interval to the T-
wave peak, TCRT=total cosine R-to-T, TMD=T-wave morphology dispersion, TPE=T-wave peak to T-
wave end interval, TWR=T-wave residuum. With permission, from Porthan et al. 2007, Relationship of 
electrocardiographic repolarization measures to echocardiographic left ventricular mass in men with 
hypertension, J Hypertens 2007;25(9):1951–7. 
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Table 4 Effects of 4-week antihypertensive drug treatment (drug compared to placebo) on clinical and ECG parameters in study II (n=183). 
 Placebo§ Losartan Bisoprolol Amlodipine HCTZ 
Systolic blood pressure (mmHg)   152±13 143±16‡   139±15‡   144±13‡   147±15‡ 
Diastolic blood pressure (mmHg) 100±7 92±9‡   90±9‡   93±8‡   97±8‡ 
Heart rate (beats per minute)   62±7 63±8†   53±7‡     65±10‡   65±9‡ 
QRS area sum (µV×s)   370±81 362±84‡ 372±83 370±84   379±84‡ 
QRS (ms)   87±8 87±10 88±9   87±10 88±9 
Serum potassium¶ (mmol/L)     4.4±0.2 4.4±0.3     4.6±0.3‡   4.4±0.3     4.1±0.3‡ 
Maximum QTendNc (ms)   401±20 395±20‡   394±21‡ 399±19 402±20 
Mean QTendNc (ms)     387±16   382±16‡    381±19‡   386±16   388±17 
Maximum QTpeakNc (ms)   331±16 327±17‡   325±18‡ 330±17 330±18 
Mean QTpeakNc (ms)     314±13   311±14‡    309±17‡   314±15   314±16 
Maximum TPE V1–6 (ms)     83±10   81±12†   82±12   82±11     85±12‡ 
Mean TPE (ms)     72±7   70±7‡     71±7*   72±7     75±8‡ 
PCA ratio (%)   14.4±5.4  13.9±5.8* 14.2±5.7 14.1±5.7 14.4±5.9 
TMD (°)   13.3±9.2  12.9±9.6‡     12.6±10.5† 13.0±9.3   13.3±10.1 
TCRT (unitless)     0.41±0.45   0.44±0.48†     0.45±0.45†   0.41±0.49   0.41±0.50 
Values are expressed as mean±standard deviation. *P<0.05, †P<0.01, ‡P<0.001. §Mean of measurements from all placebo periods. ¶n=91 for bisoprolol and 
losartan, n=92 for amlodipine and HCTZ. P values from the Wilcoxon signed ranks test (TMD, TCRT), the paired samples t test (serum potassium), or from the 
repeated measures analysis of variance (all other variables). ECG=electrocardiographic, HCTZ=hydrochlorothiazide, Nc=nomogram-corrected for heart rate, 
PCA=principal component analysis, QTend=QT interval to the T-wave end, QTpeak=QT interval to the T-wave peak, TCRT=total cosine R-to-T, TMD=T-wave 
morphology dispersion, TPE=T-wave peak to T-wave end interval. 
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Figure 7 Percentage changes in repolarization measures after 4-week drug treatment in study II. P values 
(drug compared to placebo) as in Table 4. *P<0.05, †P<0.01, ‡P<0.001. HCTZ=hydrochlorothiazide, 
Max=maximum, Nc=nomogram-corrected for heart rate, PCA=principal component analysis, QTend=QT 
interval to the T-wave end, QTpeak=QT interval to the T-wave peak, TCRT=total cosine R-to-T, TMD=T-
wave morphology dispersion, TPE=T-wave peak to T-wave end interval. Reproduced with permission of 
Informa Medical and Pharmaceutical Science - journals, from Annals of Medicine, Short-term 
electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive 
men, Porthan et al. 2009a, Volume 41, Pages 29–37, Copyright 2009; Permission conveyed through 
Copyright Clearance Center, Inc. 
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with shortening of QTend intervals (r from 0.14 to 0.16, P<0.001) and TPE intervals (r 
from 0.17 to 0.28, P<0.001). A decrease in serum potassium level was associated with 
prolongation of QT intervals (r from –0.12 to –0.27, P from 0.020 to <0.001) and TPE 
intervals (r from –0.28 to –0.37, P<0.001). In multivariate analyses, a decrease in 
systolic blood pressure and QRS area sum as well as an increase in serum potassium 
level remained weak but significant independent predictors of the shortening of QTend 
and TPE intervals. This was also obseved when the potential effects of baseline 
echocardiographic LVMI and placebo systolic blood pressure on these repolarization 
parameters were adjusted. 
 
5.3 Relationship of common gene variants to repolarization parameters  
   (studies III and IV) 
 
In the population cohort of 5043 subjects (46.6% men) in study III, mean age was 
51.4±14.1 years. Table 5 shows the relationship between SNPs and the QTend interval. 
The KCNE1 D85N minor allele was associated with a 10.5-ms prolongation of the age-, 
gender-, and heart rate-adjusted QTend interval. When the study population was stratified 
according to the genotype, mean QTendNc interval was 393±20 ms in D85N major 
homozygotes (n=4684), 404±20 ms in D85N heterozygotes (n=127), and 415±23 ms in 
D85N minor homozygotes (n=3). Also the minor alleles of KCNH2 rs3807375, SCN5A 
H558R, and the four strongly correlating NOS1AP SNPs (r2 between 0.77 and 0.97) 
were associated with QT-interval prolongation. Table 5 also shows that minor alleles of 
KCNH2 K897T and R1047L were associated with QT-interval shortening, although the 
effect was modest and the significance level was borderline for R1047L. To evaluate the 
impact of the four QT-interval altering SNPs of KCNE1 D85N, KCNH2 K897T and 
rs3807375, and NOS1AP rs2880058, a score calculating the additive effect of the SNPs 
was constructed for each study subject based on their genotype. Using this score, a 
linear association was found (P<0.00001) between the score and QT interval, with a one 
point increase in the score associated with a 0.89-ms prolongation of the age-, gender-, 
and heart rate-adjusted QTend interval. For each quintile of the score, the adjusted QTend 
interval increased by 2.4 ms (P<0.00001). 
In the population cohort of 5890 subjects (45.2% men) in study IV, mean age was 
52.1±14.3 years. Table 5 shows the relationship between SNPs and the TPE interval. 
The KCNH2 K897T minor allele was associated with a 1.2-ms shortening and the 
KCNH2 rs3807375 minor allele was associated with a 0.8-ms prolongation of TPE 
interval. For the four NOS1AP SNPs, minor alleles were associated with TPE-interval 
shortening, with the effect varying from –0.5 to –0.8 ms. When SNP effects on QTpeak 
and QTend intervals were analysed, it was observed that, for NOS1AP, the association 
with QTpeak interval was stronger than with QTend interval, resulting in TPE-interval 
shortening. For all SNPs in studies III and IV, the results for QT interval and TPE 
interval were tested also with the genotypic genetic models and this did not change the 
results. 
The relationship of SNPs to T-wave morphology parameters (PCA ratio, TMD, TCRT, 
TWR) was analysed in study IV. The multivariate regression analyses showed that the 
KCNH2 K897T minor allele was associated with a 0.03-unit decrease in normalized 
TWR (P=0.039), the NOS1AP rs4657139 minor allele was associated with a 0.04-unit 
decrease in normalized TCRT (P=0.042), and that the NOS1AP rs10494366 minor allele 
37
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Table 5 Relationship between SNPs and QT interval* in study III as well as between SNPs and TPE interval† in study IV. 
∆ QT interval  ∆ TPE interval   
Gene 
 
 
SNP 
Allele‡ and 
respective amino 
acid change Per minor allele (ms) P  Per minor allele (ms) P 
rs1805123 A→C, K897T   –2.6 <0.00001  –1.2   0.00005 
rs3807375 G→A   +1.6 <0.00005  +0.8   0.001 
KCNH2 
rs36210421 G→T, R1047L   –1.5 <0.049    
 C→G, R190G   –0.5 <0.85    
rs1805124 A→G, H558R   +1.5 <0.002    
SCN5A 
 C→A, A572D   +0.5 <0.66    
rs1805128 G→A, D85N +10.5 <0.00001  –1.3   0.202 KCNE1 
rs1805127 G→A, G38S   +0.4 <0.29    
KCNE2 rs2234916 A→G, T8A   +0.1 <0.98    
rs2880058 A→G   +4.0 <0.00001  –0.6   0.013 
rs4657139 T→A   +4.0 <0.00001  –0.5   0.032 
rs10918594 C→G   +3.9 <0.00001  –0.8   0.002 
NOS1AP 
rs10494366 T→G   +3.5 <0.00001  –0.6   0.018 
*Mean QTend interval of all leads, heart rate nomogram-correction. †Maximum TPE interval of precordial leads. ‡Major→minor 
allele. Using a stepwise linear regression analysis, QT interval and TPE interval were adjusted for the clinical covariates and the 
output residuals were saved as a variable. Age and gender were used as covariates for QT interval. Age, gender, Cornell voltage-
duration product, systolic blood pressure, history of coronary heart disease, and history of previous myocardial infarction were 
used as covariates for TPE interval. In the second linear regression analysis, the output residual was used as the dependent and the 
genotype as the independent variable. Results shown are from additive models (see description in the Statistical analyses section). 
Data values represent differences from major homozygotes, which were used as a reference. SNP=single nucleotide 
polymorphism, TPE=T-wave peak to T-wave end interval. 
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 was associated with a 0.04-unit decrease in normalized TCRT (P=0.034). For all other 
SNPs, the results were non-significant (both allelic and genotypic genetic models 
tested). When the three SNPs with significant results were tested with genotypic 
models, only the relationship between KCNH2 K897T and TWR was found to be 
statistically significant (P=0.040). 
 
5.4 Predictive value of repolarization parameters for mortality (study V) 
 
Table 6 shows the clinical characteristics of the study population in study V. In this 
population cohort, mean follow-up time was 71±9 months (5.9±0.8 years). Of the 5917 
study subjects, 335 (5.7%) died during the follow-up (9.6 deaths per 1000 person years 
of follow-up). In men and women, all-cause mortality was 6.5% and 5.0% (P=0.015), 
and cardiovascular mortality was 2.8% and 1.7% (P=0.006), respectively. Of all 335 
deaths, 131 (39%) were cardiovascular deaths. 
 
 
Table 6 Clinical characteristics of the study population in study V. 
 Men (n=2674) Women (n=3243) 
Age (years)   50.9±13.3   53.1±14.9 
Current smoking (%) 27.8 17.2 
Body mass index (kg/m²) 27.1±4.1 26.7±5.1 
Total cholesterol/HDL ratio   5.3±1.8   4.3±1.4 
ECG LVH (%) 20.2 15.7 
Systolic blood pressure (mmHg) 135.4±18.8 133.3±22.5 
Diastolic blood pressure (mmHg)   84.4±10.7   79.8±10.8 
Hypertension (%) 50.0 44.2 
Diabetes mellitus (%)   6.8   4.6 
Coronary heart disease (%)   7.6   5.7 
Previous myocardial infarction (%)   3.4   1.4 
Values are expressed as mean±standard deviation for continuous variables and percentages for categoric 
variables. For all variables, differences between the genders were statistically significant (P<0.05). 
ECG=electrocardiographic, HDL=high density lipoprotein, LVH=left ventricular hypertrophy. 
 
 
Table 7 shows the ECG repolarization parameters for men and women according to 
survival status. Study subjects who died had longer ECG repolarization duration (QT 
interval) and higher degree of ECG repolarization heterogeneity (TWR) than those who 
survived. In addition, those who died had further changes in T-wave morphology 
(higher values of PCA ratio and TMD, lower values of TCRT), except that in men the 
differences were statistically non-significant for TCRT (all-cause and cardiovascular 
mortality) and TWR (all-cause mortality). In univariate Cox analyses, QT interval and 
with a few exceptions all T-wave morphology parameters were significant univariate 
mortality predictors in both genders. The only non-significant univariate predictors were 
TCRT in men (all-cause and cardiovascular mortality) and TWR in men (all-cause 
mortality). Kaplan-Meier curves for TMD in men and TWR in women are shown in 
Figures 8 and 9, respectively. 
 39
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Table 7 ECG repolarization parameters in men and women according to survival status in study V. 
 All-cause mortality    Cardiovascular mortality   
 
Alive 
(Men: n=2501, 
Women: n=3081) 
Dead 
(Men: n=173, 
Women: n=162) 
 
 
P 
 
Alive or non-cardiovascular 
death (Men: n=2599, 
Women: n=3187) 
Dead 
(Men: n=75, 
Women: n=56) 
 
 
P 
QT interval* (ms)        
    Men 400±22 410±22 <0.0001  400±22 415±25 <0.0001 
    Women 412±21 420±23 <0.0001  412±21 425±23 <0.0001 
PCA ratio (%)        
    Men 13.3±6.8 17.9±9.9 <0.0001  13.5±7.0   19.4±10.5 <0.0001 
    Women 16.9±8.7   20.9±12.2 <0.0001  17.0±8.7   23.7±16.1 <0.0002 
TMD (°)        
    Men   13.0±12.3   21.4±18.1 <0.0001    13.2±12.5   25.4±20.1 <0.0001 
    Women   15.0±13.1   23.6±20.5 <0.0001    15.2±13.3   28.4±23.8 <0.0001 
TCRT (unitless)        
    Men   0.32±0.56   0.26±0.59 <0.262    0.32±0.56   0.27±0.55 <0.306 
    Women   0.41±0.47   0.26±0.61 <0.036    0.41±0.47   0.00±0.68 <0.0001 
TWR (technical units)        
    Men   18083±24872   18439±15932 <0.071    17998±24508   21871±19714 <0.002 
    Women   15505±21379   19484±16168 <0.0001    15583±21192   22539±18456 <0.0001 
Values are expressed as mean±standard deviation. *Maximum QTend interval of all leads, heart rate nomogram-correction. ECG=electrocardiographic, 
PCA=principal component analysis, TCRT=total cosine R-to-T, TMD=T-wave morphology dispersion, TWR=T-wave residuum. Reprinted from Heart Rhythm, 
Volume 6, Porthan et al. 2009b, Predictive value of electrocardiographic QT interval and T-wave morphology parameters for all-cause and cardiovascular 
mortality in a general population sample, Pages 1202–8, Copyright 2009, with permission from Elsevier. 
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Figure 8 Kaplan-Meier curves (with log-rank tests) for TMD in men. Groups are stratified by above and 
below median values. Hazard ratios (HR) with 95% confidence intervals (CI) are also shown. Plus 
symbols indicate censoring times: a study subject has experienced non-cardiovascular death (in the panel 
showing cardiovascular mortality), or a study subject has not died by the end of the follow-up (both 
panels). TMD=T-wave morphology dispersion. Reprinted from Heart Rhythm, Volume 6, Porthan et al. 
2009b, Predictive value of electrocardiographic QT interval and T-wave morphology parameters for all-
cause and cardiovascular mortality in a general population sample, Pages 1202–8, Copyright 2009, with 
permission from Elsevier. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 Kaplan-Meier curves (with log-rank tests) for TWR in women. Groups are stratified by above 
and below median values. Hazard ratios (HR) with 95% confidence intervals (CI) are also shown. Plus 
symbols indicate censoring times: a study subject has experienced non-cardiovascular death (in the panel 
showing cardiovascular mortality), or a study subject has not died by the end of the follow-up (both 
panels). TWR=T-wave residuum, t.u.=technical units. Reprinted from Heart Rhythm, Volume 6, Porthan 
et al. 2009b, Predictive value of electrocardiographic QT interval and T-wave morphology parameters for 
all-cause and cardiovascular mortality in a general population sample, Pages 1202–8, Copyright 2009, 
with permission from Elsevier. 
m
ul
at
iv
e 
A
C
 m
or
ta
lit
y 0,12
0,09
0,06
0,03
0,00 C
um
ul
at
iv
e 
C
V 
m
or
ta
lit
y 0,06
0,04
0,02
0,001337      1304       1263       1221     Number 
1337      1328       1317       1305     at risk 
TMD <10.3 ° 
P<0.0001 
TMD ≥10.3 ° 
1337     1304     1263       1221     Number 
1337      1328      1317       1305     at risk 
TMD <10.3 ° 
P<0.0001 
TMD ≥10.3 ° HR 3.6 (95% CI 2.5–5.1) HR 8.7 (95% CI 4.2–18.1) 
 
0.12 
 
0
 
0
 
0
 
.09 
.06 
. 3 
0.00 
 .  .  
Follow-up (months)
806040200
C
um
ul
at
iv
e 
A
C
 m
or
ta
lit
y 0,12
0,09
0,06
0,03
0,00 1622     1592     1568       1535     Number   
1621      1610      1598       1581     at risk 
TWR <10978 t.u. 
P<0.0001 
TWR ≥10978 t.u. 
Follow-up (months)
806040200
C
um
ul
at
iv
e 
C
V 
m
or
ta
lit
y 0,06
0,04
0,02
0,00 1622       1592     1568       1535     Number 
1621       1610      1598       1581     at risk 
TWR <10978 t.u. 
P<0.0001 
TWR ≥10978 t.u. 
HR 2.0 (95% CI 1.5–2.8) HR 3.7 (95% CI 2.0–7.1)  
 
.  
 
.  
 
.  
 
.  
 
.  
.  
 
 
.  
 
 
.  
 
 
.  
 
C
um
ul
at
iv
e 
al
l-c
au
se
 m
or
ta
lit
y 
 
.  
 
.  
 
.  
 
.  
C
um
ul
at
iv
e 
al
l-c
au
se
 m
or
ta
lit
y  
 
C
um
ul
at
iv
e 
ca
rd
io
va
sc
ul
ar
 m
or
ta
lit
y 
.  
 
 
.  
 
 
.  
C
um
ul
at
iv
e 
ca
rd
io
va
sc
ul
ar
 m
or
ta
lit
y 
 
 
41
  
 
 
42
RESULTS                            
Table 8 shows mortality hazard ratios (HRs) from multivariate Cox models for ECG 
repolarization parameters. After adjusting for covariates in men, each 1-SD increase in 
loge TMD was associated with a 1.3-fold [95% confidence interval (CI) 1.1–1.6] risk of 
cardiovascular death, and TMD above the median value was associated with a 4.4-fold 
(95% CI 2.1–9.4) risk of cardiovascular death when compared to TMD below the 
median value. After adjusting for covariates in women, each 1-SD increase in loge TWR 
was associated with a 1.3-fold (95% CI 1.01–1.6) risk of cardiovascular death, and 
TWR above the median value was associated with a 2.2-fold (95% CI 1.1–4.2) risk of 
cardiovascular death when compared to TWR below the median value. The QT interval 
and TCRT in men, as well as QT interval, PCA ratio, and TMD in women did not 
remain as independent mortality predictors. Multivariate Cox models using non-
cardiovascular mortality (excluding cardiovascular deaths from all-cause mortality) as 
the dependent variable were also performed, and it was found that QT interval and T-
wave morphology parameters were not independent predictors of non-cardiovascular 
mortality. 
In comparative respective univariate Cox models using the QT interval with Bazett’s 
formula adjustment for heart rate, the QTc interval was a significant univariate predictor 
of all-cause and cardiovascular mortality in both genders, with longer QTc interval 
indicating higher risk. In multivariate Cox models in men, the QTc interval was an 
independent predictor of all-cause mortality, with each 1-SD increase in the QTc 
interval associated with a 1.2-fold (95% CI 1.02–1.4, P=0.030) risk of all-cause death. 
In contrast, the QTc interval was not an independent predictor of cardiovascular 
mortality in men (P from 0.087 to 0.219). In women, the QTc interval did not remain as 
an independent mortality predictor in multivariate Cox models (P from 0.116 to 0.500). 
In both genders, the TPE interval was not a significant mortality predictor in univariate 
or multivariate Cox models (multivariate Cox model P from 0.404 to 0.992). 
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Table 8 Mortality hazard ratios from the multivariate Cox proportional hazards models for ECG repolarization parameters in men and women in study V. 
 All-cause mortality  Cardiovascular mortality 
 
 
Continuous 
variables* 
  
Median- 
dichotomized 
variables† 
  
 
Continuous 
variables* 
  
Median- 
dichotomized 
variables† 
 
 HR (95% CI) P  HR (95% CI) P  HR (95% CI) P  HR (95% CI) P 
Men            
    QT interval‡ 1.02 (0.9–1.2) 0.782  1.01 (0.7–1.4) 0.953  1.1   (0.9–1.3) 0.549  1.2 (0.7–2.2) 0.449 
    PCA ratio 1.2   (1.1–1.4) 0.007  1.4   (1.02–2.0) 0.037  1.2   (1.02–1.5) 0.034  2.3 (1.2–4.1) 0.008 
    TMD 1.1   (1.0–1.3) 0.055  2.1   (1.4–3.0) 0.0001  1.3   (1.1–1.6) 0.014  4.4 (2.1–9.4) 0.0001 
    TCRT 0.97 (0.8–1.1) 0.625  0.8   (0.6–1.1) 0.272  0.97 (0.8–1.2) 0.798  0.9 (0.6–1.4) 0.584 
    TWR 1.05 (0.9–1.2) 0.525  1.1   (0.8–1.5) 0.655  1.2   (1.01–1.5) 0.044  1.5 (0.9–2.4) 0.120 
Women            
    QT interval‡ 1.03 (0.9–1.2) 0.732  1.1   (0.8–1.6) 0.505  1.2   (0.9–1.6) 0.138  1.4 (0.8–2.6) 0.261 
    PCA ratio 0.98 (0.8–1.1) 0.767  1.03 (0.7–1.4) 0.857  1.1   (0.9–1.4) 0.424  1.1 (0.6–2.0) 0.675 
    TMD 1.1   (0.9–1.3) 0.254  1.3   (0.9–1.8) 0.143  1.1   (0.9–1.4) 0.367  1.4 (0.7–2.6) 0.297 
    TCRT 0.9   (0.8–1.1) 0.270  0.9   (0.7–1.3) 0.708  0.7   (0.5–0.9) 0.006  0.6 (0.3–1.2) 0.131 
    TWR 1.2   (1.01–1.3) 0.039  1.4   (0.97–1.9) 0.070  1.3   (1.01–1.6) 0.040  2.2 (1.1–4.2) 0.018 
*Hazard ratio was calculated per standard deviation increment in the repolarization parameter, and variable distributions were normalized with loge 
transformation (PCA ratio, TMD, TWR) or with the Blom method (TCRT). †Hazard ratio was calculated as the risk in the above-median group compared to the 
below-median group. ‡Maximum QTend interval of all leads, heart rate nomogram-correction. Significant clinical predictors from univariate Cox models were 
entered into each multivariate model as covariates if significant univariate correlation existed (together with one repolarization measure at a time). In men, 
significant predictors of all-cause and cardiovascular mortality were age, current smoking (all-cause mortality only), systolic blood pressure, diastolic blood 
pressure (all-cause mortality only), hypertension, coronary heart disease, myocardial infarction, diabetes mellitus, and ECG LVH (cardiovascular mortality 
only). Respectively in women, significant predictors were age, body mass index (all-cause mortality only), systolic blood pressure, total cholesterol/high density 
lipoprotein ratio, hypertension, coronary heart disease, myocardial infarction, diabetes mellitus, and ECG LVH. CI=confidence interval, 
ECG=electrocardiographic, HR=hazard ratio, LVH=left ventricular hypertrophy, PCA=principal component analysis, TCRT=total cosine R-to-T, TMD=T-
wave morphology dispersion, TWR=T-wave residuum. 
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6 DISCUSSION 
 
6.1 Left ventricular mass as a repolarization modifier (study I) 
 
Epidemiological evidence demonstrates that LVH is an independent risk factor for 
cardiovascular morbidity and mortality (Levy et al. 1990, Vakili et al. 2001, Bombelli et 
al. 2009) as well as for sudden cardiac death (Haider et al. 1998). Furthermore, 
experimental studies imply that marked LVH is associated with arrhythmogenic 
structural and electric myocardial changes (Kowey et al. 1991, Ben-David et al. 1992, 
Yan et al. 2001, Kozhevnikov et al. 2002, Jin et al. 2010). These epidemiological and 
experimental findings together strongly indicate that in advanced LVH, sudden cardiac 
death may be mediated, at least in part, by arrhythmogenic repolarization mechanisms. 
Based on both experimental and simulation studies, repolarization changes at the 
cellular level in marked LVH are also expected to prolong the QT interval and change 
T-wave morphology in body surface ECG (Zabel et al. 1995, Yan et al. 1998, 
Bacharova et al. 2010). In agreement with this, QT-interval prolongation and T-wave 
morphology changes have been observed in patients with high LVMI values (Oikarinen 
et al. 2001a, 2002). 
In the general population, subjects with marked LVH form a group with high relative 
cardiovascular risk. However, an even larger group is formed by mildly or moderately 
hypertensive individuals with minor structural remodelling, which nonetheless is also 
associated with increased risk (Schillaci et al. 2000). Consequently, the significance of 
minor structural remodelling and mild LVH at the population level may be high, 
although the risk increase in individuals may be relatively low. Of note, in a 
hypertensive population, the absolute number of subjects developing new-onset 
ischemic heart disease was higher in subjects with minor, non-specific ECG 
repolarization changes than in those with ECG repolarization strain pattern (Schillaci et 
al. 2004). 
ECG repolarization changes were assessed in study I and were seen to be already 
detectable in hypertensive men with minor LV structural changes. All ECG 
repolarization parameters were significantly different in LVH subjects compared to non-
LVH subjects when using a dichotomous echocardiographic LVH cutoff value. In 
addition, when using continuous variables, LVMI correlated linearly with all 
repolarization parameters despite the relatively narrow LVMI range. The independent 
relationship of LVMI to QTend interval, TPE intervals, and T-wave morphology 
parameters was verified with multivariate analyses. 
Study I suggests that in subjects with hypertensive mild LVH, a reduced 
repolarization reserve and an increased ventricular repolarization heterogeneity may 
already be present. This may indicate that, in hypertension, the correlation between mild 
LVM increase and increased cardiovascular risk (Schillaci et al. 2000) may in part be 
explained by unfavourable repolarization changes. These repolarization changes are 
probably not directly arrhythmogenic, however they may modify arrhythmia 
vulnerability and become significant in conjuction with other factors affecting 
repolarization unfavourably, for example during ischemia, electrolyte imbalances, or 
use of QT-interval prolonging drugs. Mechanisms of the changes observed in T-wave 
morphology parameters may only be speculated, but they may be related to alterations 
in ion channel function, intercellular uncoupling, or unidentified subtle cardiac 
structural changes. 
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6.2 Antihypertensive drugs as repolarization modifiers (study II) 
 
In study II, an angiotensin II blocker losartan and a ß-blocker bisoprolol showed 
beneficial effects on ECG repolarization. A thiazide diuretic hydrochlorothiazide 
prolonged the TPE interval, potentially reflecting an adverse repolarization effect, 
whilst the effects of calcium-channel blocker amlodipine on ECG repolarization were 
nonsignificant. There are no previous studies on the short-term repolarization effects of 
these drugs. 
Activation of the RAAS plays a central role in the adverse outcomes of hypertension 
including LVH, myocardial fibrosis, and heart failure (Weber and Brilla 1991, Kim and 
Iwao 2000, Mehta and Griendling 2007, Tomaschitz et al. 2010). Angiotensin II and 
aldosterone exert several potentially direct proarrhythmic mechanisms, such as 
promoting myocardial fibrosis, hypertrophy, and ischemia; increasing intracellular 
calcium concentration; causing depletion of potassium and magnesium; increasing the 
activity of the sympathetic nervous system; and modulating voltage-dependent 
potassium channels (Delpón et al. 2005). Experimentally, drugs that inhibit the RAAS 
have shown potentially rapid antiarrhythmic actions by blunting these mechanisms, and 
losartan with its metabolite also have direct effects on cardiac potassium channels 
(Caballero et al. 2000, Delpón et al. 2005). Previous clinical studies have found that 
long-term antihypertensive treatment, particularly with angiotensin-converting enzyme 
inhibitors and angiotensin II receptor blockers, is associated with beneficial changes in 
ventricular repolarization (González-Juanatey et al. 1998, Malmqvist et al. 2002). 
Antihypertensive drugs inhibiting RAAS may also be more efficient in LVH regression 
compared to other drugs (Ruilope and Schmieder 2008). Thus, the beneficial 
repolarization changes in the previous studies are probably in part explained by LV 
structural reverse remodelling (Rials et al. 1998, Rials et al. 2001). In study II, however, 
the favourable repolarization changes with losartan treatment occurred rapidly. The 
magnitude of blood pressure reduction was associated weakly and only with some of the 
studied ECG repolarization measures, suggesting that repolarization changes were only 
partly explained by blood pressure reduction. The results suggest that in hypertension, 
losartan may also have direct clinically beneficial modifying effects on ventricular 
repolarization that are likely to be independent of structural reverse remodelling. 
ß-blockers are generally considered to be antiarrhythmic because they decrease the 
incidence of presumably arrhythmic sudden cardiac death, for example in congestive 
heart failure and congenital LQTS (Huikuri et al. 2001, Zicha et al. 2006). ß-blockers 
are particularly effective in preventing arrhythmias in LQTS type 1 (Priori et al. 2004), 
and in these patients use of ß-blockers is associated with beneficial ECG repolarization 
effects (Viitasalo et al. 2006). In addition to preventing arrhythmia-promoting actions of 
ß-adrenergic stimulation, ß-blockers may also decrease RAAS activity (Blumenfeld et 
al. 1999). Study II indicates that, also in hypertensive patients, bisoprolol may have 
short-term protective repolarization effects which are not dependent on LV reverse 
remodelling. 
Hydrochlorothiazide treatment was associated with an increase in QRS area sum, 
which was used as an estimate for changes in LVM and has performed better than 
standard ECG criteria in LVH detection (Okin et al. 1998, Oikarinen et al. 2004a). 
Although blood pressure decreased with all treatments, QRS area sum increased during 
hydrochlorothiazide and decreased during losartan, whereas bisoprolol and amlodipine 
had no significant effects, suggesting that direct blood pressure-dependent effects 
cannot explain this finding. In addition, no changes in QRS duration were observed, 
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suggesting that none of the drugs influenced ventricular conduction. QRS amplitudes 
are determined by LVM, but also by intracardiac blood volume, distance of the heart 
from the chest wall, and the relation between LV wall thickness and chamber dilation 
(Surawicz 1986). The short-term increase in QRS area sum with hydrochlorothiazide 
was surprising because significant short-term LVM changes were not expected. This 
finding may reflect volume changes (Surawicz 1986). However, since losartan 
antagonizes and hydrochlorothiazide activates the RAAS (Burnier and Brunner 1992, 
Mehta and Griendling 2007), whilst angiotensin II has cardiotrophic effects, it is 
possible that the observed changes in QRS area sum may also reflect true changes in 
electrically active LVM. Hydrochlorothiazide treatment was also associated with a 
decrease in serum potassium, which in turn was independently associated with TPE-
interval prolongation. Hypokalemia prolongs QT interval and is a well-known risk 
factor for arrhythmias (Roden 2006). Additionally, in epidemiological studies, relatively 
short-term hydrochlorothiazide treatment, with much higher drug doses, has been 
associated with an increased incidence of sudden cardiac death in hypertensive patients 
(Siscovick et al. 1994, Hoes et al. 1995). It is suggested in the present study that in 
addition to RAAS activation, the hypokalemic effect that increases ventricular 
repolarization heterogeneity may partly mediate the increased risk of sudden death with 
high-dose hydrochlorothiazide treatment. Thus, a potential mechanism whereby high 
dose of hydrochlorothiazide causes TPE-interval prolongation may partly explain the 
previous epidemiological observations. However, increased incidence of sudden death 
due to low-dose hydrochlorothiazide therapy has not been reported. In addition, 
although the observed TPE-interval prolongation during hydrochlorothiazide is 
potentially an unfavourable modifying effect, the clinical significance of prolonged TPE 
interval needs to be studied further. 
 
6.3 Common gene variants as repolarization modifiers (studies III and IV) 
 
6.3.1 KCNH2 K897T and rs3807375 
 
Experimental studies indicate that the KCNH2 K897T substitution may have multiple 
effects on cellular electrophysiology (Bezzina et al. 2003, Paavonen et al. 2003, Anson 
et al. 2004, Gentile et al. 2008), suggesting that predicting the net effect of this SNP on 
ECG ventricular repolarisation may prove difficult. In several previous population 
studies, K897T has been shown to slightly shorten the ECG QT interval (Bezzina et al. 
2003, Gouas et al. 2005, Pfeufer et al. 2005, Newton-Cheh et al. 2007), but also neutral 
(Raitakari et al. 2009) and opposite associations have been reported (Pietilä et al. 2002, 
Koskela et al. 2008). In a few reports with small sample sizes in LQTS patients, both 
protective and harmful impacts have been suggested for the minor variant 897T 
(Laitinen et al. 2000, Crotti et al. 2005, Zhang et al. 2008). In two recent studies 
(Newton-Cheh et al. 2009, Pfeufer et al. 2009), K897T was not among the genome-wide 
significant variants associated with QT interval. However, K897T is strongly correlated 
with two KCNH2 variants (rs2968863 and rs2968864) which were associated with QT-
interval shortening (Newton-Cheh et al. 2009, Pfeufer et al. 2009). Recently, it has been 
suggested that the effect of K897T may vary, depending on whether it is inherited in cis 
or in trans with the disease-causing allele (Hedley et al. 2009). In line with the majority 
of the previous studies, it was shown in study III that the 897T variant is associated with 
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QT-interval shortening in the general population. In study IV, this variant also 
shortened the TPE interval but did not consistently alter T-wave morphology 
parameters. 
There are no experimental studies that characterize the functional properties of 
KCNH2 intronic SNP rs3807375 in cardiac repolarization. Previously, the minor allele 
of this variant has been reported to prolong QT interval in a general population sample 
(Newton-Cheh et al. 2007). In line with this, the minor allele of rs3807375 was shown 
to be associated with QT-interval prolongation in study III. However, results from 
recent genome-wide studies suggest that this association may not be independent of 
other SNPs (Newton-Cheh et al. 2009, Pfeufer et al. 2009). In study IV, the minor allele 
of rs3807375 had no effects on T-wave morphology parameters but prolonged the TPE 
interval. In LQTS type 2, which is caused by mutation of KCNH2 resulting in reduced 
IKr, the typical feature of resting ECG is the prolongation of QT and TPE intervals 
(Shimizu and Antzelevitch 1998, Gima and Rudy 2002, Viitasalo et al. 2002). Thus, the 
findings of study III and IV suggest that that the minor allele of rs3807375 may be 
associated with reduced IKr and with reduced repolarization reserve. 
 
6.3.2 KCNE1 D85N 
 
The KCNE1 D85N polymorphism causes variation in minK, the regulatory subunit of 
the ion channel mediating IKs (Lehmann-Horn and Jurkat-Rott 1999). Given previous 
experimental studies, the minor 85N variant most likely reduces potassium current in 
this channel (Westenskow et al. 2004), and a reduction also in IKr was recently reported 
(Nishio et al. 2009). The 85N variant may thus predispose to acquired LQTS and 
modify the phenotype of congenital LQTS (Nishio et al. 2009). In experimental LQTS 
type 1 models, IKs block prolongs action potential duration but does not increase 
transmural dispersion at rest (Shimizu and Antzelevitch 1998). However, transmural 
dispersion is increased in conjunction with ß-adrenergic stimulation (Shimizu and 
Antzelevitch 1998). Previous clinical studies have suggested that the 85N variant is 
associated with drug-induced TdP (Paulussen et al. 2004, Mank-Seymour et al. 2006) 
and with QT-interval prolongation in healthy individuals (Gouas et al. 2005), and is 
more common in LQTS patients than in healthy controls (Nishio et al. 2009). A few 
studies in healthy individuals did not find association between the D85N polymorphism 
and the QT interval (Aydin et al. 2005, Friedlander et al. 2005). Genome-wide 
association analysis supports the independent association between the 85N variant and 
QT-interval prolongation (Newton-Cheh et al. 2009). Study III, showing a substantial 
10.5-ms prolongation in the QT interval for each D85N minor allele, also supports the 
association with QT-interval prolongation and was the first study to show the 
association in a large general population sample. Despite the marked QT-interval 
prolongation, the 85N variant had no effect on ECG TPE interval or T-wave 
morphology measures (study IV). In ambulatory ECG recordings from patients with 
LQTS type 1, the TPE interval was only prolonged significantly at high heart rates 
(Viitasalo et al. 2002). Thus, the findings from resting ECGs showing that the 85N 
variant prolongs the QT but not the TPE interval are consistent with a reduction in IKs. 
Whether this polymorphism is associated with TPE-interval prolongation during 
physical exercise remains to be studied. 
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6.3.3 NOS1AP variants 
 
Overexpression of CAPON, which is the product of NOS1AP and functions as a ligand 
of nitric oxide synthase 1, results in up-regulation of nitric oxide synthase 1-nitric oxide 
signalling pathways, leading to decreased ICa,L and increased IKr, and to action potential 
shortening in guinea pigs (Chang et al. 2008). If one postulated that genetic NOS1AP 
variants reduce CAPON levels, then increased ICa,L, decreased IKr, and prolonged action 
potential are expected (Crotti et al. 2009). However, species differences in CAPON 
function may occur, such as for the zebrafish where the opposite effect is observed with 
the loss of NOS1AP expression that leads to action potential shortening (Milan et al. 
2009). In addition to the effects on repolarization, nitric oxide synthase has a role in a 
number of cardiac physiological processes including contractility and calcium cycle (Xu 
et al. 1999, Barouch et al. 2002, Burkard et al. 2007, Oceandy et al. 2007, Asada et al. 
2009). 
The minor alleles of several NOS1AP variants have been associated with a longer QT 
interval in several population studies (Arking et al. 2006, Aarnoudse et al. 2007, Post et 
al. 2007, Lehtinen et al. 2008, Tobin et al. 2008, Raitakari et al. 2009). Genome-wide 
association studies have recently reported four independent SNPs (rs12029454, 
rs12143842, rs16857031, rs4657178) located in or near NOS1AP (Newton-Cheh et al. 
2009, Pfeufer et al. 2009). Furthermore, recent studies have reported the disease-
modifying effect of NOS1AP variants in LQTS (Crotti et al. 2009, Tomás et al. 2010), 
and that NOS1AP variants associate with sudden cardiac death in the general population 
(Eijgelsheim et al. 2009, Kao et al. 2009). In a large population cohort of white adults 
(Kao et al. 2009), two variants (rs16847548, rs12567209) were associated with sudden 
cardiac death, but the effect was independent of QT-interval duration in multivariate 
analyses. The authors suggested that the QT interval might not be a sufficient measure 
of ventricular repolarization or the prognostic value of NOS1AP variants might be 
mediated by some other mechanisms than repolarization. 
The association of minor alleles of four strongly correlating NOS1AP SNPs with 
longer QT interval was confirmed in study III. In study IV, these NOS1AP variants were 
associated with a shorter TPE interval but had no effects on T-wave morphology. 
Together with the QT-interval prolongation effect, TPE-interval shortening was an 
unexpected finding. Interestingly, the results suggest a stronger prolongation effect of 
NOS1AP SNPs on the QTpeak in comparison to the QTend interval. Whether the TPE-
interval shortening is mediated by increased ICa,L or by some other mechanism remains 
to be studied. 
 
6.3.4 Other gene variants 
 
The SCN5A R190G and A572D have been found to be enriched in LQTS (Paulussen et 
al. 2003, Fodstad et al. 2004). For KCNE1 G38S, both QT-interval prolonging 
(Friedlander et al. 2005) and null effects have been reported (Aydin et al. 2005, Akyol 
et al. 2007, Gouas et al. 2007). The KCNE2 T8A has been found to be enriched in drug-
induced LQTS (Sesti et al. 2000, Paulussen et al. 2004), and an association with QT-
interval prolongation was observed in healthy individuals (Aydin et al. 2005). However, 
no association with the QT interval was observed in a larger general population sample 
(Pfeufer et al. 2005). For all these four SNPs, the association with QT interval was non-
significant in study III, and thus these variants seem not to modify resting ECG 
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repolarization duration in Finns. In in vitro studies, KCNH2 R1047L has been reported 
to impair IKr density (Chevalier et al. 2007), but on the other hand, Anson et al. (2004) 
found no functional differences between R1047L and wild type KCNH2 channel. Sun et 
al. (2004) reported KCNH2 R1047L to be associated with drug-induced LQTS. In study 
III, R1047L was associated with a slight QT-interval shortening. However, the 
statistical significance was borderline (P=0.049), and it seems unlikely that this SNP is 
a true modifier of QT interval in this population. In agreement with the results of study 
III, genome-wide association was not found between R190G, A572D, G38S, T8A, and 
R1047L, and the QT interval in individuals of European ancestry (Newton-Cheh et al. 
2009, Pfeufer et al. 2009). 
The SCN5A gene is associated with various types of cardiac diseases (Hedley et al. 
2009), and the SCN5A H558R polymorphism has also been associated with an extensive 
list of cardiac abnormalities. The H558R has disease-modifying effects in in vitro 
models of a conduction disease (Viswanathan et al. 2003), LQTS type 3 (Ye et al. 
2003), and sick sinus syndrome (Gui et al. 2010). Clinically, H558R has been found to 
be a genetic modifier in Brugada syndrome (Lizotte et al. 2009), complete 
atrioventricular block (Chevalier et al. 2007), and to be associated with early onset atrial 
fibrillation (Chen et al. 2007). The 558R variant prolonged the QT interval in healthy 
twins (Aydin et al. 2005) and in a general population sample (Gouas et al. 2005). 
Recent studies did not find significant genome-wide association between H558R and 
the QT interval (Newton-Cheh et al. 2009, Pfeufer et al. 2009). In study III, a modest 
QT-interval prolongation for this SNP with a P value of 0.002 was seen. However, 
considering the number of previous population studies and the number of SNPs tested, 
the evidence of the association between the H558R polymorphism and the QT interval 
in the general population was considered to be unresolved in study III. 
 
6.3.5 Impact of the findings in common gene variants 
 
Study III confirmed several common gene variants to be associated with the duration of 
QT interval. Consistent with previous studies, the association was relatively modest for 
most of the SNPs, and these SNPs are unlikely to play a major role in arrhythmogenesis 
in individuals. However, even a small increase in individual risk may eventually 
contribute significantly to the absolute number of arrhythmias at the population level. 
The association for KCNE1 D85N was markedly stronger and possibly indicates that 
carriers of 85N variant(s) may be more susceptible to repolarization-related arrhythmias 
than non-carriers. 
The SNPs showing a significant association with QT interval in study III were, for 
the first time in a large study population, further analysed in study IV for a possible 
association with the TPE interval and T-wave morphology parameters. The minor allele 
of KCNH2 K897T shortened, and the minor allele of KCNH2 rs3807375 prolonged, 
both the QT and TPE intervals. Thus, the results indicate that these SNPs have a 
modifying effect on IKr. Consistent with a reduction in IKs, KCNE1 D85N was not 
associated with the TPE interval. None of the studied SNPs showed reliable association 
with ECG T-wave morphology parameters, suggesting that these polymorphisms do not 
mediate the observed prognostic value of T-wave morphology parameters in the general 
population (study V). Also, neither the TPE interval nor the reported T-wave 
morphology parameters seem to clarify the previously observed association between 
NOS1AP variants and sudden cardiac death (Eijgelsheim et al. 2009, Kao et al. 2009). 
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6.4 Repolarization parameters as mortality predictors (study V) 
 
The QT interval is a measure of repolarization duration and is clinically used to detect 
short QT syndrome and LQTS, and to evaluate disease- and drug-related repolarization 
effects. The majority of previous epidemiological studies in the general population 
suggest that QT-interval prolongation may be, at the most, a weak risk factor for 
mortality (Montanez et al. 2004). The observed prognostic value in the previous studies 
may be in part affected by study methods, for example different heart rate-adjustment 
formulas. In the present study, QT intervals were adjusted for heart rate with gender-
specific nomograms derived from the same study population, and a valid QT-interval 
measurement technique was used. With this robust methodology, rate-adjusted QT 
interval was a significant univariate predictor of mortality, but when adjusted for other 
clinical predictors, the QT interval did not contain independent prognostic value. To 
compare these results to previous epidemiological studies, analyses using Bazett-
corrected QT interval were also performed, and the QTc interval remained only in men 
as a weak independent predictor of all-cause mortality. Thus, the results suggest that in 
the general population, QT-interval prolongation may be considered as a surrogate for, 
and no more informative than, the other clinical risk factors. 
As the QT interval measures only temporal variation in repolarization duration, it 
may not detect changes in T-wave morphology. In contrast, T-wave morphology 
parameters measure temporospatial changes of the ventricular repolarization. As 
ventricular repolarization, T-wave morphology, and susceptibility to arrhythmias are 
interrelated (Burgess 1979, Kuo et al. 1983), non-invasive quantification of changes in 
T-wave morphology could be useful in risk evaluation. Several studies have shown the 
potential prognostic value of T-wave morphology parameters in various patient groups 
including patients with cardiovascular diseases (Zabel et al. 2002), myocardial 
infarction (Zabel et al. 2000, Batchvarov et al. 2004, Malik et al. 2004, Perkiömäki et al. 
2006), systolic heart failure (Huang et al. 2009), diabetes mellitus (Okin et al. 2004b), 
and end-stage renal disease (Lin et al. 2007). The prognostic value of these parameters 
in the general population has also been reported in a few previous epidemiological 
cohort studies, performed in US Indians (Okin et al. 2002), elderly Dutch inhabitants, 
and postmenopausal US women (Rautaharju et al. 2006a,b). 
Study V extends the previous findings on T-wave morphology to a large, mainly 
Caucasian representation of the Finnish population aged 30 years and over. Concerning 
the T-wave morphology parameters used in the present study, study V is at present the 
largest on their predictive value in the general population. As a methodological strength, 
all analyses were performed separately for both genders, and the results suggest that T-
wave morphology parameters have gender differences in their numerical values. With a 
few exceptions all T-wave morphology parameters were significant mortality predictors 
in univariate analyses in both genders. However, when other significant clinical 
predictors were used as covariates in multivariate analyses, PCA ratio and TMD were 
the only significant independent predictors of both all-cause and cardiovascular 
mortality in men. In contrast in women, the PCA ratio and TMD lost their prognostic 
value in multivariate analyses, and the independent mortality predictors were TCRT 
(cardiovascular mortality) and TWR (all-cause and cardiovascular mortality). Thus, 
study V suggests that T-wave morphology parameters have gender-related differences 
also in their predictive value, implicating that in risk evaluation these measures should 
probably be assessed separately in men and women. Also an important finding of study 
V was that T-wave morphology parameters were not independent predictors of non-
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cardiovascular mortality, indicating that these measures are specifically related to 
cardiovascular mortality. 
 
6.5 Study strengths and limitations 
 
Study strengths. Studies I and II: Comorbidities were thoroughly screened and 
excluded. Consequently, the study population represented subjects with essential 
hypertension and without other diseases which potentially could have modified 
repolarization measures. Echocardiograms were performed by a single, experienced 
cardiologist, and the recordings were analysed by a single observer in a blinded fashion. 
Study protocol with cross-over design and intervening placebo periods was suitable to 
minimize both the subject-specific drug responses and the potential carryover effects 
from previous antihypertensive treatment. 
Studies III–V: Study population was large and is representative of the entire Finnish 
adult population. The clinical and genetic data were collected prospectively and 
systematically. 
Studies I–V: ECGs were high-quality digital recordings and all leads were recorded 
simultaneously. ECG measurements were performed in a blinded fashion with validated 
measurement techniques by a single observer. The intraobserver variability of the 
measurements was low. 
 
Study limitations. Studies I and II: The studies included Caucasian male study 
subjects, and the results may not be applicable to women or other races. LVM was 
determined using echocardiography, which has limitations compared to other 
techniques, such as magnetic resonance imaging. The prevalence of LVH was low, and 
we cannot exclude the possibility that previous antihypertensive treatments may have 
caused reverse structural remodelling without reverse electric remodelling. Study II 
does not provide information on the repolarization effects of antihypertensive drug 
combinations or repolarization effects of long-term treatment, and the results are 
directly applicable only to the drugs and doses used. The antihypertensive drug doses 
used in study II did not lower blood pressure equally, and a decrease in systolic blood 
pressure may directly affect ventricular repolarization favourably by stretch-mediated 
mechanisms (Eckardt et al. 2001). On the other hand, blood pressure change was 
associated weakly and only with some of the studied ECG repolarization measures. 
Studies III–V: Study subjects in these studies were derived from the Finnish general 
population, which consists almost totally of Caucasians. The distribution of studied 
SNPs may differ between populations. Hence, conclusions drawn from these studies 
may not be applicable to other races or populations with different genetic backgrounds. 
Our analyses included four strongly correlating NOS1AP SNPs, and some other SNPs 
not examined in the present study may have different repolarization effects and 
prognostic value. 
Studies I–V: These studies used ECG surrogate markers of arrhythmia vulnerability 
and do not provide direct arrhythmia data. The exact electrophysiological basis of T-
wave morphology parameters is currently unknown. 
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7 CONCLUSIONS 
 
Mild LVM increase in essential hypertension is associated with potentially adverse 
repolarization changes. This finding may carry risk implications at the population level 
for the large number of hypertensive patients. 
Antihypertensive drugs have divergent short-term ECG repolarization effects. 
Losartan and bisoprolol have beneficial effects on the QT interval, TPE interval, and T-
wave morphology parameters. Hydrochlorothiazide may have unfavourable effects on 
the TPE interval, and the effects of amlodipine on ECG repolarization seem to be 
neutral. Therefore, ventricular repolarization may be modified by the type of 
antihypertensive drug also in the beginning of the therapy, before LVH regression with 
potentially beneficial repolarization reverse remodelling of long-term treatment occurs. 
The KCNE1 D85N SNP is associated with a marked QT-interval prolongation in the 
Finnish general population. This variant may potentially independently increase 
susceptibility to repolarization-related arrhythmias. In addition, KCNH2 K897T and 
rs3807375, as well as the studied NOS1AP variants are associated with modest 
alterations in the durations of QT and TPE intervals, confirming their roles as mild 
repolarization modulators. In contrast, the studied SNPs seem not to be consistently 
associated with T-wave morphology parameters, suggesting that these polymorphisms 
do not mediate the prognostic value of T-wave morphology parameters. 
In the general population, when other risk factors of mortality are taken into account, 
T-wave morphology parameters, but not the QT interval or TPE interval, provide 
independent and thus potentially clinically useful risk assessment data. The independent 
prognostic value of these parameters seems to be gender-specific and is specifically 
related to cardiovascular mortality. 
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APPENDICES 
 
Appendix 1. Disease definitions in studies IV and V. 
 
1. Hypertension was present if any of 1.a–1.c were fulfilled: 
1.a In the National Register of Rights to Reimbursements for Medical Costs,* a diagnosis 
of hypertension was present at the time of the study baseline 
1.b In the health examination, arterial mean (two measurements) systolic blood pressure 
≥140 mmHg or mean (two measurements) diastolic blood pressure ≥90 mmHg 
1.c Use of antihypertensive medication prescribed by a physician 
 
2. Coronary heart disease was present if any of 2.a–2.g were fulfilled: 
2.a In the physician’s clinical examination,† a history of previous angina pectoris‡ was 
considered to be certain (other options, but not accepted here, were: no previous angina 
pectoris, possible previous angina pectoris) 
2.b In the National Hospital Discharge Register,§ a diagnosis code of myocardial 
infarction or other ischemic heart disease [International Classification of Diseases 
(ICD) -8 or ICD-9 codes 410–414 or ICD-10 codes I20–I25] was present at the time of 
the study baseline or before the study baseline 
2.c In the National Register of Rights to Reimbursements for Medical Costs,* a diagnosis 
of chronic coronary heart disease was present at the time of the study baseline or 
before the study baseline 
2.d In the physician’s clinical examination,† there was history of a previous coronary 
artery bypass surgery 
2.e In the physician’s clinical examination,† there was history of a previous coronary 
angioplasty 
2.f In the home interview,¶ there was history of a previous coronary artery bypass surgery 
2.g In the home interview,¶ there was history of a previous coronary angioplasty 
 
3. Previous myocardial infarction was present if any of 3.a–3.c were fulfilled: 
3.a In the physician’s clinical examination,† previous myocardial infarction was 
considered to be certain (other options, but not accepted here, were: no previous 
myocardial infarction, possible previous myocardial infarction) 
3.b In the ECG Minnesota coding, large Q waves indicating probable previous myocardial 
infarction were observed (Minnesota codes 1.1 or 1.2 together with codes 5.1–5.2) 
3.c In the National Hospital Discharge Register,§ a diagnosis code of a myocardial 
infarction (ICD-8 or ICD-9 code 410 or ICD-10 codes I21–I23) was present at the time 
of the study baseline or before the study baseline 
 
4. Diabetes mellitus was present if 4.a or 4.b (or both) were fulfilled: 
4.a Use of blood glucose-lowering medication 
4.b Four-hour fasting venous plasma glucose ≥7.0 mmol/L 
 
*In Finland, individuals with hypertension or coronary heart disease are entitled to 
reimbursement for medication costs. To obtain the right, they have to apply for it and append a 
medical certificate by a physician to show that they fulfill the objective criteria of the disease. 
†In the physician’s clinical examination, the physician critically assessed clinical history and 
available documents and performed a structured clinical examination. ‡Defined as typical chest 
pain brought on by exertion and relieved by nitroglycerine or rest. §The Finnish hospital 
discharge register is valid for identifying major coronary heart disease events (Pajunen et al. 
2005). ¶Performed by a trained interviewer (by Statistics Finland’s interview organisation). 
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Appendix 2. Computation of TCRT, TMD, and TWR. 
 
This appendix follows the guidelines previously published for TCRT and TMD (Acar et al. 
1999), and for TWR (Malik et al. 2000). The original guidelines were modified by correcting 
the baseline wander (point 5), by using 90 ms for the epsilon value (point 5), and by modifying 
the T-wave detection to be more suitable for signal with silent ST segments (point 6). Upper-
case bold letters are used for matrices and lower-case bold letters for vectors. Vector or matrix 
followed by time index in parenthesis, (t), refers respective index or column in the vector or 
matrix, respectively. 
 
1. Create matrix M (size 8×nsamp; nsamp is the number of samples in the data) with leads I, 
II, V1, V2, V3, V4, V5, V6 in each row of the matrix. The matrix must contain ECG 
traces from one beat, and the traces have to start at least 50 ms before the P wave and last 
at least 50 ms after the T wave. 
 
2. Correct baseline wander for each lead (rows in M): 
a Find a 40 ms window with the lowest SD 250–350 ms before the QRS complex 
(preceding TP interval) and another 400–500 ms after the QRS complex (following 
TP interval). 
b In both windows, calculate the point matching the average time and average amplitude 
of the window. Then, define a straight line through these two points. 
c Subtract the fitted line from the data (row in M). 
 
3. Do singular value decomposition (Wall et al. 2003) for M and formulate the 2- and 3-
dimensional subspaces (from the original 8 dimensional space): 
 
a                           , where Σ is a 8×8 diagonal matrix (diag(σ1, σ2, … , σ8)) and 
σ1≤σ2≤σ8≤0. 
b                                                      and                                    , , where si are signal 
vectors spanned by ui. 
 
4. Define the energy for S3D(t):                                    . 
 
5. Detect the QRS complex (t’RS, t’RE, tRS, tRE) from e3D(t): 
a Detect the maximum e3D(t). 
b Define t’RS as the time point where e3D(t) decreases below 70% of the maximum value 
before the maximum e3D(t), and t’RE as the time point where e3D(t) decreases below 
70% after the maximum e3D(t). 
c Define tRS as the time point 90 ms before t’RS, and tRE as the time point 90 ms after the 
t’RS. 
 
6. Detect the T wave (tTS, tTP, tTE) from e3D(t): 
a Define tTP as the time of the maximum value in e3D(t) after the tRE. 
b Define tTS:                                                          . 
c Define tTE: 
i Determine the maximum and minimum values for s1 and s2. 
ii Divide both ranges to 10 bins, and create a 10×10 matrix. 
iii Compute the number of times that S2D(t) hits each cell of the matrix. 
iv Determine the mean and SD of the number of hits in non-zero cells. 
v Determine the threshold value as mean + mu · SD of hits, where mu is set to 3. 
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vi If the threshold value is below the maximum hit value, decrease mu 0.2 at a time 
until the maximum value is reached. 
vii Start from the beginning of S2D(t) and count hits to the matrix cells until the 
threshold value is reached. If the threshold value is reached before tTP, increase 
mu by 0.2 and formulate a new threshold value. Continue counting until the new 
threshold value is reached. If tTP has not still been passed, keep repeating the last 
two phases until it has. Define tTE as the time instant (after the tTP) where the 
threshold value is reached. 
 
7. Normalize the signals so that the maximum energy of the signals is 1: 
                                                                               . 
 
8. Subtract the direct-current vector from the signals: direct-current vector is defined as the 
average of amplitude values at tRS, tRE, tTS, and tTE. 
 
9. Define the energy e'3D(t) from the direct-current corrected S'3D(t):                                    . 
 
10. Define TCRT: 
a Define t'TP as the time instant of maximum value in e'3D(t) after the tTS. 
b Define TCRT as the average cosine of the angle between QRS complex and T-wave: 
 
                                                                                                                . 
 
11. Define TMD: 
a Reconstruct M' from S3D (by multiplying it left with U), and do another singular value 
decomposition for signal between tTS and tTE only. 
b Normalize the two biggest left singular vectors by scaling them with singular values. 
c Formulate 21 pairs from the seven (I, II, V2, V3, V4, V5, V6; V1 is dropped off) 2D 
reconstruction vectors ({I, II}, {I, V2}, … , {V5, V6}). 
d Define TMD as the average angle [0°, 180°] between the 21 pairs. 
 
12. Define TWR: 
a Do singular value decomposition for the original 8 leads from tTS to tTE. 
b Define TWR as the sum of the singular values from 4 to 8. 
 
Calculation data in appendix 2 are given by Heikki Väänänen Lic Sc (Tech). 
